NCT ID: [STUDY_ID_REMOVED]
CVIA 076 – Version 5.[ADDRESS_992470] OF FIGURES  .................................................................................................................... 6  
ABBREVIATIONS AND ACRONYMS  .................................................................................. 7  
INVESTIGATOR’S AGREEMENT  ....................................................................................... [ADDRESS_992471] INFORMATION .................................................................. 12  
PROTOCOL SUMMARY  ....................................................................................................... 14  
 BACKGROUND AND RATIONALE  ........................................................................ 20  
 Burden of Disease ....................................................................................................... 20  
 Pathogen ...................................................................................................................... 21  
 Description of Study Vaccine ..................................................................................... 21  
 Summary of Nonclinical Studies of Study Vaccine  ................................................... 23  
1.4.1  Growth and yield in Vero cells .......................................................................... 24  
1.4.2  Antigenicity ........................................................................................................ 25  
1.4.3  Immunogenicity ................................................................................................. 25  
1.4.4  Attenu ation phenotypes ..................................................................................... 26  
 Summary of Clinical Studies of Study Vaccine  ......................................................... 26  
1.5.1  Safety  ................................................................................................................. 27  
1.5.2  Immunogenicity ................................................................................................. 28  
1.5.3  Viral Shedding ................................................................................................... 28  
1.5.4  Genetic Stability ................................................................................................. 28  
 Overall Development Strategy  .................................................................................... 28  
 HYPOTHESIS, OBJECTIVES AND ENDPOINTS  ................................................... 28  
 Study Hypotheses........................................................................................................ 28  
 Study Objectives  ......................................................................................................... 29  
2.2.1  Primary Objective:  ............................................................................................. 29  
2.2.2  Secondary Objectives:  ....................................................................................... 29  
2.2.3  Exploratory Objectives: ..................................................................................... 29  
 Study Endpoints .......................................................................................................... 29  
2.3.1  Primary Endpoints: ............................................................................................ 29  
2.3.2  Secondary Endpoints: ........................................................................................ 30  
2.3.3  Exploratory Endpoints:  ...................................................................................... 30  
 STUDY DESIGN  ......................................................................................................... 31  
 STUDY POPULATION ............................................................................................... 32  
CVIA 076 – Version 5.[ADDRESS_992472] Description ........................................................................................... 34  
5.1.2  Manufacturer ...................................................................................................... 35  
5.1.3  Presentation and Formulation  ............................................................................ 35  
5.1.4  Stability and Storage  .......................................................................................... 35  
 Dose Preparation and Administration  ......................................................................... 36  
 Accountability and Disposal  ....................................................................................... 36  
 STUDY PROCEDURES  .............................................................................................. 36  
 Recruitment  ................................................................................................................. 36  
 Study Visits  ................................................................................................................. 36  
6.2.1  Screening – Day -[ADDRESS_992473] Vaccination Visit – Day 1 Visit  ................................................................. 37  
6.2.3  Day 8 Visit, 7 (+1) days after the study vaccination – Clinic follow -up 
visit..................................................................................................................... 39  
6.2.4  Day 29 Visit, 28 (+2) days after the study vaccination – Clinic follow -up 
visit..................................................................................................................... 39  
6.2.5  Day 36 Visit, 7 (+1) days after the second study vaccination – Clinic 
follow-up visit .................................................................................................... 41  
6.2.6  Day 57 Visit, 28 (+2) days after the second study vaccination – Clinic 
follow-up visit .................................................................................................... 41  
6.2.7  Day 169 Telephone Visit, 168 (+14) days after the initial study 
vaccination – Final Study Visit  .......................................................................... 42  
6.2.8  Unscheduled Visits  ............................................................................................ 43  
 Discontinuation of Vaccination or Study Procedures ................................................. 43  
 Withdrawal from Study............................................................................................... 43  
 Loss to Follow-up ....................................................................................................... 44  
 Use of Concomitant Medications During the Study  ................................................... 44  
 Emergency Unblinding ............................................................................................... 45  
 Management of Birth Control and Pregnancy During Study...................................... 45  
 Clinical Assessments  .................................................................................................. 45  
 LABORATORY EVALUATIONS/REQUIREMENTS  ............................................. 46  
 Sample Collection, Distribution and Storage.............................................................. 46  
 Clinical Laboratory Tests  ............................................................................................ 47  
 Assessment of Shed Poliovirus ................................................................................... 47  
 Future Use of Stored Samples..................................................................................... 48  
CVIA 076 – Version 5.[ADDRESS_992474] Containment  .............................................................................................. 48  
 SAFETY ASSESSMENT AND REPORTING  ........................................................... 48  
 Definitions ................................................................................................................... 48  
8.1.1  Adverse Event (AE)  ........................................................................................... 48  
8.1.2  Adverse reaction / Suspected Adverse Reaction (21CFR Part 312.32) ............. 49  
8.1.3  Serious Adverse Event (SAE) ............................................................................ 50  
 Reporting Period and Parameter ................................................................................. 50  
 Severity of Adverse Events ......................................................................................... 50  
 Causality of Adverse Event ........................................................................................ 52  
 Follow-up of Adverse Event ....................................................................................... 52  
 General Guidance on Recording Adverse Events ....................................................... 53  
 Reporting of SAEs ...................................................................................................... 53  
 Protocol Deviations ..................................................................................................... 54  
 SAFETY OVERSIGHT  ............................................................................................... 55  
 Routine Reviews by [CONTACT_726840] (PSRT)  ...................................... 55  
 Independent Data Monitoring Committee (IDMC) Reviews ..................................... 55  
 Study Pause Rules ....................................................................................................... 55  
 Study Pause Procedure ................................................................................................ 56  
 DATA HANDLING and RECORDKEEPI[INVESTIGATOR_1645]  ............................................................ 56  
 Definitions ................................................................................................................... 56  
10.1.1  Source Data  ........................................................................................................ 56  
10.1.2  Source Documents ............................................................................................. 57  
 Data Capture Methods (Case Report Form Development and Completion)  .............. 57  
 Data Management  ....................................................................................................... 57  
 Retention of Study Records ........................................................................................ 57  
 STATISTICAL CONSIDERATIONS  ......................................................................... 58  
 Overview and General Design  .................................................................................... 58  
 Randomization Procedures ......................................................................................... 58  
 Sample Size  ................................................................................................................. 58  
 Definitions of Populations to be Analyzed ................................................................. 61  
11.4.1  Enrolled Population ........................................................................................... 61  
11.4.2  Safety Population ............................................................................................... 61  
11.4.3  Full Analysis Population  .................................................................................... 61  
11.4.4  Per-Protocol Population ..................................................................................... 61  
11.4.5  Other Populations............................................................................................... 62  
 Analytical Methodology  ............................................................................................. 62  
11.5.1  Descriptive Methodology................................................................................... 62  
CVIA 076 – Version 5.0 
17 February  2022 
 5  11.5.2  Analysis Sequence  ............................................................................................. 62  
11.5.3  Changes in Analysis Plan ................................................................................... 62  
11.5.4  Baseline and Demographic Characteristics, and Participant Disposition  .......... 62  
11.5.5  Safety Analysis  .................................................................................................. 63  
11.5.6  Immunogenicity Analysis .................................................................................. 64  
11.5.7  Viral Shedding Analysis .................................................................................... 65  
11.5.8  Genetic Stability Analyses  ................................................................................. 66  
11.5.9  Handling of Dropouts and Missing Data ........................................................... 67  
 QUALITY ASSURANCE AND QUALITY CONTROL  ........................................... 67  
 General Considerations ............................................................................................... 67  
 Study Monitoring ........................................................................................................ 67  
 Independent Auditing.................................................................................................. 68  
 Regulatory Agency Auditing ...................................................................................... 68  
 ETHICAL CONSIDERATIONS (AND INFORMED CONSENT) ............................ 68  
 Ethical Standards  ........................................................................................................ 68  
 Ethical Review  ............................................................................................................ 68  
 Informed Consent Process .......................................................................................... 68  
 Participant Confidentiality  .......................................................................................... 69  
 Reimbursement ........................................................................................................... 69  
 Risk and Benefits ........................................................................................................ 70  
 Reporting to Local Health Department  ....................................................................... 71  
 Compensation for Research Related Injury ................................................................ 71  
 FINANCING AND INSURANCE  .............................................................................. 72  
 PUBLICATION POLICY ............................................................................................ 72  
 REFERENCES ............................................................................................................. 73  
APPENDICES  .......................................................................................................................... 74  
APPENDIX 1:  SCHEDULE OF STUDY VISITS AND EVALUATIONS  .......................... [ADDRESS_992475] OF TABLES 
Table 1: Genetic modifications of Sabin -2 in nOPV2 -c1 and their purposes. .............................. 22  
Table 2: Methods and crite ria on which nOPV1 was evaluated.  .................................................. 24  
Table 3: Methods and criteria on which nOPV3 was evaluated. .................................................. 25  
Table 4: Grading scale to grade the severity of solicited AEs  ...................................................... 50  
Table 5: Grading scale to grade the severity of abnormal clinical safety laboratory test results 
reported as AEs ............................................................................................................ 51  
 
CVIA 076 – Version 5.[ADDRESS_992476] OF FIGURE S 
Figure 1: Modifications in nOPV1 and nOPV3 viruses.  .............................................................. 23  
CVIA 076 – Version 5.0 
17 February  2022 
 
 7  ABBREVIATIONS AND ACRONYMS  
 
Ab  A ntibody  
AE  Adverse E vent  
ALT  Alanine Transaminase  
AUC   Area Under the Curve  
BSL-2  Biosafety Level 2  
CBC  Complete Blood Count  
CCID 50  Cell Culture Infectious Dose 50%  
CDC  U nited States  Centers for Disease Control  and Prevention  
cDNA   Complementary D eoxyribonucleic Acid 
CFR  Code of Federal R egulations  
CI  Confidence Interval  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -[ADDRESS_992477] Research Organization  
CSR  Clinical Study Report  
CTA  Clinical Trial Agreement  
cVDPV   c irculating Vaccine -Derived Poliovirus  
DM  Data Management  
DRM   Data Review Meeting  
eCRF  Electronic Case Report Form  
EIA  Enzyme I mmunoassay  
FAP  Full Analysis Population  
FDA  ([LOCATION_002]) Food and Drug Administration  
CVIA 076 – Version 5.0 
17 February  2022 
 
 8  FOCP  Female of C hildbearing Potential  
GCP  Good C linical Practice  
GMFR   Geometric Mean Fold Rise  
GMT   Geometric Mean Titer  
HBV   Hepatitis B Virus  
HCV   Hepatitis C Virus  
HIV  Human Immunodeficiency Virus  
IB  Investigator ’s Brochure  
ICF  Informed Consent Form  
ICH  International Council for  Harmoni sation  
ICMJE   International Committee of Medical Journal Editors  
IDMC   Independent Data Monitoring Committee  
IEC  Independent Ethics Committee  
IgA  Immunoglobulin A  
IgG  Immunoglobulin G  
IND  Investigational New Drug  
IPV  I nactivated Poliovirus Vaccine  
IRB  Institutional Review Board  
 
IWRS   Interactive Web Response System  
LLN  Lower Limit of Normal  
LLOQ   Lower Limit of Quantification  
MedDRA  Medical Dictionary for Regulator y Activities  
mg  milligram  
mL  milliliter  
mOPV  monovalent Oral Polio myelitis  Vaccine (Sabin)  
NAb  Neutralizing Antibody  
CVIA 076 – Version 5.[ADDRESS_992478]   Upper Limit of N ormal  
ULOQ   Upper Limit of Quantification  
US(A)   [LOCATION_002] (of America)  
UTR  Untranslated Region  
VAPP  Vaccine -Associated Paralytic Polio  
VDPV   Vaccine -Derived Poliovirus  
CVIA 076 – Version 5.0 
17 February  2022 
 
 10  VS  Vital Signs  
WBC   White Blood Cell  
WHO   World Health Organization  
WPV   Wild Poliovirus  
  
CVIA 076 – Version 5.0 
17 February  2022 
 
 11  INVESTIGATOR’S AGREEMENT  
 
 
Protocol Title : A first -in-human, phase 1, randomized, observer- blind, controlled study to 
assess the safety and immunogenicity of  novel live attenuated type 1 and type 3 oral 
poliomyelitis vaccines in healthy adults  
 ‘The signature [CONTACT_726926], including all statements regarding confidentiality, and according to local legal and regulatory requirements and ICH E6 guidelines .’ 
 
_______________________________________________    _______________  
Signature [CONTACT_789]  [INVESTIGATOR_726817]  
 
 _______________________________________________    _______________  
Signature [CONTACT_789]  [INVESTIGATOR_726817]  
 
 
_______________________________________________    _______________  
Signature [CONTACT_789]  [INVESTIGATOR_726817]  
 
 
_______________________________________________    _______________  
Signature [CONTACT_726927] 076 – Version 5.[ADDRESS_992479] -in-human, phase 1, randomized, observer -blind, controlled study to assess 
the safety and immunogenicity of  novel live attenuated type 1 and type 3 oral 
poliomyelitis  vaccine s in healthy adults  
Short Title  Phase 1 study of novel types 1 and 3 oral poliomyelitis  vaccines  
Protocol 
Number  CVIA 076  
Trial 
Registration  ClinicalTrials.gov: [STUDY_ID_REMOVED]  
FDA Reference 
Number  BB-IND 026305  
Trial Phase  Phase 1 
Investigational 
Products  Novel oral poliomyelitis  vaccines  (nOPVs) :   
• Novel OPV  type 1 (nOPV1), containing 106.5 CCID 50/dose, manufactured by [CONTACT_726841], Indonesia  
• Novel OPV  type 3 (nOPV3), containing 106.5 CCID 50/dose, manufactured by [CONTACT_726841], Indonesia  
Both nOPVs are live, attenuated polioviruses derived from a modified Sabin 
type -2 infectious c omplementary deoxyribonucleic acid (cDNA ) clone and 
propagated in Vero cells. Modifications were introduced in the viral nucleotide 
sequences in part of the 5ʹ -untranslated region  (UTR)  to improve the genetic 
stability of this major attenuating determinant of Sabin type -2, and two 
modifications were made in the 3D polymerase to further improve stability of 
the attenuation and reduce recombination. In addition, a key replicati on 
element was relocated from the 2C coding region to the 5ʹ  UTR to reduce the 
risk of loss of stabilized 5’ UTR through recombination. The cDNA plasmid was 
then further modified by [CONTACT_726842] (P1) region of the genome 
with the capsid from a Sabin- 1 (nOPV1) or Sabin- 3 (nOPV3) clone, generating 
chimeric viruses with novel type 2 non- structural regions coupled with Sabin-
1 or - 3 structural proteins.  
In addition to the attenuated poliovirus, the vaccine formulation includes 
sucrose, acetic acid or NaHCO 3, and Basal Medium Eagle (BME) solution.  
Active control m onova le nt oral poliomyelitis  vaccines (mOPVs), Sabin :   
• Sabin mOPV1 containing not less than 106.0 CCID 50/dose, manufactured by 
[CONTACT_726843] (Indonesia)  
• Sabin mOPV3 containing not less than 105.8 CCID 50/dose, manufactured by 
[CONTACT_726843] (Indonesia)  
The live types 1 & 3 OPVs contain suspensions of types 1 and 3 attenuated 
poliom yelitis viruses (Sabin strains) prepared in primary monkey kidney cell s. 
Each dose (2 drops = 0.1 m L) of the two vaccines contains not less than 106.0 
CVIA 076 – Version 5.0 
17 February  2022 
 
 15  infective units of type 1 and 105.8 of type 3, respectively. Sucrose is used as a 
stabilizer. The vaccines may contain trace amounts of not more than 2 mcg 
erythromycin and not more than 10 mcg kanamycin.  
Study 
Hypotheses  Safety  
• The live attenuated , novel  oral polio myelitis  vaccine  type 1 (nOPV1) is safe 
and well -tolerated in healthy adults  
• The live attenuated , novel  oral polio myelitis  vaccine  type 3 (nOPV3) is safe 
and well -tolerated in healthy adults  
Immunogenicity  
• nOPV1 and nOPV3 elicit demonstrable immune responses  in healthy 
adults  
Study 
Objectives  
  
  
 
 
 Primary Objective:    
Safety  
• To evaluate the safety and tolerability of nOPV1 and nOPV3 in healthy 
adults  
Secondary Objectives:  
Immunogenicity  
• To assess the humoral immune responses ( neutralizing antibody titers ) 
elicited by [CONTACT_726844]1 and nOPV3, and compare to  that of mOPV1 and mOPV3, 
respectively, in healthy adults  
Fecal Shedding o f Study Vaccine Virus es 
• To assess the duration of fecal shedding (as determined by [CONTACT_940] [ PCR]) of nOPV1 and nOPV3 after the initial dose and 
compare to that of the homotypic mOPV s 
• To assess the rate of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3  and compare to that of the homotypic mOPVs  in participant s with 
an exclusive inactivated poliovirus vaccine ( IPV) prior vaccination histor y 
• To assess the extent of shedding (as determined by a shedding index endpoint [SIE] and the area under the curve [AUC]) of nOPV1 and nOPV 3 
and compare to that of the homotypic mOPVs  in participant s with an 
exclusive IPV prior vaccination history  
Exploratory Objectives : 
• To assess the duration of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3 after the second dose and compare to that of the homotypic 
mOPVs  
• To assess the rate of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3  and compare to  that of the homotypic mOPVs
 in participant s with 
an OPV-containing prior vaccination histor y 
CVIA 076 – Version 5.0 
17 February  2022 
 
 16  • To assess the extent of shedding (as determined by [CONTACT_726845]) 
of nOPV1 and nOPV3 and compare to that of the homotypic mOPVs in 
participant s with an OPV-containing prior vaccination history 
• To assess the potential for neurovirulence of nOPV shed virus as measured 
by a transgenic mouse neurovirulence assay, and compare to  that of 
mOPV1 and mOPV3  
• To assess genetic stability of nOPV shed virus as determined by [CONTACT_11398] -
generation sequencing (NGS)  
• To assess the humoral immune responses elicited by [CONTACT_726844]1 and nOPV3 against non- vaccine polio virus  types
 
Study Endpoints  
  
 Primary Endpoints:  
Safety:  
• Frequency of serious adverse events (SAEs) from Day 1  study vaccination 
through the end of the study 
• Frequency of solicited adverse events (AEs) for 7 days (day of study 
vaccination and 6 following days) after each dose of study vaccine  
• Frequency of unsolicited AEs for 28 days (day of study vaccination and 27 
following days) after each dose of study vaccine  [including clinically 
significant aberrant safety monitoring laboratory values on Day 8 reported 
as AEs]  
Secondary Endpoints:  
Immunogenicity:  
• Median type -specific anti-polio serum neutralizing antibody titers  at 
baseline and post -vaccination  
• Type -specific anti-polio serum neutralizing antibody Geometric Mean 
Titer ( GMT) at baseline and post -vaccination  
• Post- vaccination GMT ratios of type -specific anti-polio  serum neutralizing 
antibody, adjusted for baseline immunity  
• Post- vaccination f requency of any fold- rise (titer increased from baseline), 
a minimum 2- fold rise, and a minimum 4- fold rise  (seroconversion) , in 
type -specific anti-polio serum neutralizing antibody responses    
Fecal Shedding of Study Vaccine  Virus es  
• Time to cessation of fecal shedding (days) of the vaccine virus, following initial dose  
• Proportion of participant s shedding type -specific vaccine virus at each 
post- vaccination stool collection , as assessed by [CONTACT_726846] s with 
an exclusive IPV prior vaccination history  
• Amount of vaccine virus in each stool sample (log 10 CCID 50 per gram) 
positive for virus (PCR)  in participant s with an exclusive IPV prior 
vaccination history 
CVIA 076 – Version 5.0 
17 February  2022 
 
 17  • Shedding Index  of vaccine  virus shedding in stool , defined as the mean of 
log 10 CCID 50 per gram of stool  at 7, 14, 21 and 28 days following each dose  
in participant s with an exclusive IPV prior vaccination history 
•  AUC of vaccine virus shed in stool  in participant s with an exclusive IPV 
prior vaccination history  
Exploratory Endpoints  
• Time to cessation of fecal shedding (days) of the vaccine virus, following 
second  dose 
• Proportion of participant s shedding type -specific vaccine virus at each 
post- vaccination stool collection, as assessed by [CONTACT_726847] s with 
an OPV -containing prior vaccination history  
• Amount of vaccine virus in each stool sample (log 10 CCID 50 per gram) 
positive for virus (PCR) in participant s with an OPV -containing prior 
vaccination history 
• Shedding Index of vaccine virus shedding in stool, defined as the mean of log
10 CCID 50 per gram of stool at 7, 14, 21 and 28 days following each 
dose in participant s with an OPV -containing prior vaccination history  
• AUC of vaccine virus shed in stool in participant s with an OPV -containing 
prior vaccination history  
• Neurovirulence of shed vaccine virus from select stool samples as 
measured by a transgenic mouse neurovirulence test  
• Deep sequencing of shed vaccine virus from select stool samples using  
NGS  
• Serum neutralizing antibody titers against non- vaccine poliovirus types at 
baseline and post -vaccination   
CVIA 076 – Version 5.[ADDRESS_992480] -in-human assessment of these novel oral 
poliomyelitis  vaccines. It will be a n 8-arm, randomized, observer -blind, controlled 
trial, with Sabin monovalent vaccines serving as the control for each type  (see 
study schema, below) . 150 to 230 healthy, adult participant s will be recruited. 30 
to 40 of 60 to 80 participant s with an exclusive IPV prior vaccination history 
(cohort 1) will be randomized in a 1:1 ratio to study groups 1 and 2 and allocated 
to receive nOPV1 or mOPV1, and once these study arms are completely accrued, the other 30 to 40 exclusively -IPV vaccinated participant s (cohort 3)  
will be 
randomized in a 1:1 ratio to study groups 5 and 6 and allocated to rec eive nOPV3 
or mOPV3.  
In parallel, 45 to 75 of 90 to 150 participant s with an OPV -containing prior 
vaccination history (cohort 2) will be randomized in a 2:1 ratio to study groups 3 and 4 and allocated to receive two doses of nOPV1 or mOPV1, respectively, a nd 
once these study arms are completely accrued, the other 45 to 75 participant s 
with an OPV -containing prior vaccination history (cohort 4)  will be randomized in 
a 2:1 ratio to study groups 7 and 8 and allocated to receive two doses of nOPV3 or mOPV3, respectively.  
Study Schema 
Cohort  Group  Prior 
Vaccination  Number of 
Participant s 
(Min -Max)  Dosage  
CCID 50  Day 1  Day 29  
        
1 1 IPV 15-20 106.5  nOPV1  - 
2 15-20 ≥106  mOPV1  - 
Subtotal    30-40     
2 3 OPV  30-50 106.5  nOPV1  nOPV1  
4 15-25 ≥106  mOPV1  mOPV1  
Subtotal    45-75     
3 5 IPV 15-20 106.5  nOPV3  - 
6 15-20 ≥105 8  mOPV3  - 
Subtotal    30-40     
4 7 OPV  30-50 106.5  nOPV3  nOPV3  
8 15-25 ≥[ADDRESS_992481] week of vaccination . Participant s will be followed until 24 weeks after 
their Day 1  study vaccination. 
Study 
population  Healthy adults, 18 -45 years  of age (inclusive)  
CVIA 076 – Version 5.[ADDRESS_992482] about 7 months, allowing for 24 weeks  of follow -up 
after the receipt of the initial study vaccination.  
 
  

CVIA 076 – Version 5.0 
17 February  2022 
 
 20  
 BACKGROUND  AND RATIONALE  
Global efforts to immunize children with Sabin strain oral poliomyelitis  vaccines (OPVs) have reduced wild 
poliovirus cases by 99.9% since 1988  [1]. These vaccines have been demonstrated to be safe and interrupt 
person -to-person spread of polio viruses . However, on extremely rare occasions, use of OPV can result in 
cases of polio due to vaccine -associated paralytic polio (VAPP) and circulating vaccine -derived poliovirus 
(cVDPV) . Central to both V APP and disease induced by [CONTACT_726848] a more 
neurovirulent phenotype, which occurs during intestinal replication in vaccine recipi[INVESTIGATOR_840]. These reverted 
viruses can either cause disease in the vaccine recipi[INVESTIGATOR_726818].  In addition, the ability of cVDPVs to survive in the environment and be transmitted to others 
without being detected through acute flaccid paralysis surveillance, given most infections are asymptomatic, is a major ris k to the entire polio eradication effort . The risk of VAPP and cVDPV, in 
particular, resulted in the decision to globally discontinue routine use of Sabin type 2 OPV  (OPV 2) in April 
2016 and the planned withdrawal of  Sabin  types 1 and 3 OPV  (OPV1 and OPV3, respectively)  in the coming 
decade.  The intent of the novel OPV program is to develop more genetically stable  versions of type [ADDRESS_992483]- in-human evaluation of  novel OPVs  types 1 and 3 (nOPV1 and nOPV3, 
respectively) in healthy males and  females, from 18 to 45 years of age (inclusive) at the time of enrollment. 
Should results in adults indicate the nOPVs  are safe  and have demonstrable  immunogenicity, the y will 
progress to phase 2 testing  in target pediatric populations (young children and then infants).  
A similar novel, genetically stable  OPV  type 2  (nOPV2) strain ha s advanced into p hase 2 clinical 
development ( adults in Belgium and young children and infants in Panama) with encouraging study 
results . Since nOPV1 and nOPV3 are chimeric viruses with novel type [ADDRESS_992484] and infection with each confers type -specific life -long 
immunity to disease but little or no immunity to disease caused by [CONTACT_726849]. Over 90% of  
poliovirus infections are asymptomatic . Symptomatic disease is  more often  an acute self -limited non -
neurologic febrile illness with non -specific symptoms, such as headache, sore throat, fatigue,  and 
gastrointestinal symptoms. Less often,  disease may manifest with myalgias, meningitis, and other 
neurologic  findings, with overt paralysis occurring in less than 1% of all infections.  A major complication 
of paralytic poliomyelitis is respi[INVESTIGATOR_1399].  There are no licensed antiviral drugs available to treat 
poliomyelitis and treatment is supportive. 
Since the introduction of IPVs and OPVs in the 1950s and the launching of the Global Polio Eradication  
Initiative  campaign in 1988, transmission of wild poliovirus  (WPV)  has been interrupted in most 
CVIA 076 – Version 5.0 
17 February  2022 
 
 21  populations . Globally, type 2 WPV was declared eradicated in 2015, type 3 WPV  declared eradicated in 
2019, with current transmission of WPV  limited to type 1 and confined to a few regions within only three 
endemic countries, Nigeria, Pakistan , and Afghanistan. For the year 2019, there were 176 type 1 WPV 
cases reported , all from two of the three endemic countries, Pakistan , and Afghanistan, while there were  
365 cVDPV  cases (mostly type 2) reported, 324 of these cases from non -endemic countries  
[http://polioeradication.org]. Until all WPV  transmission is interrupted globally and eradicated, all 
countries remain at risk of importation of polio from endemic countries, especially vulnerable countries 
with weak public health and immunization services and travel or trade links to endemic countries . The 
WHO estimates that f ailure to eradicate polio from these last remaining regions  could result in a s many 
as 200, 000 new cases every year, within 10 years, all over the world. 
As long as OPV remains the vaccine used globally to achieve eradication, there remains the risk of vaccine -
derived poliovirus ( VDPV ) emergence and spread , which is why eradication of WPV is to be followed with 
cessation of OPV use in routine immunization, as was done for OPV2 in 2016, with the switch from 
trivalent OPV to bivalent OPV 1,3. In 2019, three years following the end of immunization with nOPV2, 
there has been a notable i ncrease in the number of cVDPV  type [ADDRESS_992485]  been reported, 932 (86%) of which were type 2, notwithstanding that it is estimated that 
during the same period, over 10 million cases of paralytic polio  were averted  [2]. With the eradic at ion of 
type 3 and expected eventual eradication of type 1 WPV, it is anticipated that the  concern over cVDPV  
shall remain. It is hoped that if the nOPVs prove to be safe and effective in the planned and ongoing 
studies, future cVDPV  outbreaks and associated paralytic cases  in communities with low immunity  could 
be addressed with the se novel vaccines . 
 Pathogen   
Polioviruses are small, non -enveloped viruses with a single positive strand ribonucleic acid ( RNA) genome 
of approximately 7,400 nucleotides. The genome contains a relatively long non- coding region in the 5’ 
end, referred to as 5’ untranslated region ( 5’ UTR) , which is highly structured and contains the internal 
ribosome entry site that is required for translation. The genome is translated as a single polyprotein, which 
is cleaved during translation by [INVESTIGATOR_307999] -encoded proteases into three regions referred to as P1, P2, and 
P3. The P1 region is further processed into viral structural (capsid) proteins, while P2 and P3 encode the 
non- structural proteins that are involved in protein processing and viral replication. There are three 
serotypes, defined by [CONTACT_726850] (P1) regions, with limited cross -neutralization across the three.  
 Description of Study Vaccine  
The Sabin OPV strains have been studied intensively for decades and, because of  the knowledge and 
experience gained, several approaches to the design of improved OPV strains have been investigated. In 
2011, a consortium of researchers was formed to develop improved strains, with the belief that a 
collaborative effort using a combination of strategies would have the greatest chance of success. Novel OPV (nOPV) strains were designed, produced, and tested in a variety of non- clinical studies. Two type [ADDRESS_992486] advanced into clinical development with encouraging p hase 1 and 2 study results.  
The approach to the design of nOPV strains addressed five critical inte r-related properties: cell -culture 
growth, attenuation, genetic stability (encompassing reversion through mutation and recombination), antigenicity, and immunogenicity. The designs involved innovative strategies and their success was 
assessed by [CONTACT_726851] t esting carried out in parallel for all strains to facilitate the choice of suitable 
candidates.  
CVIA 076 – Version 5.0 
17 February  2022 
 
 22  With the overall goal of seeking novel OPV1 and OPV3 (nOPV1, nOPV3) vaccines which have less chance 
of reversion to a neurovirulent phenotype and comparable im munogenicity to the current Sabin vaccines, 
one candidate for each type has been selected for clinical development thus far.  
The candidate OPV1 and OPV3 strains include [ADDRESS_992487] modifications of the Sabin- 2 genome, including 
changes to the RNA sequence in the 5’ UTR, the non- structural protein 2C, and the polymerase 3D ( Table 
1 and Figure 1) [3]. Of these modifications, only the changes to polymerase 3D result in a change in the 
amino acid sequence. The modifications aim to stabilize the genetic sequence against reversion in the 5’ 
UTR and to reduce recombination. The vaccine virus initially cont aining these modifications —a novel oral 
poliomyelitis  vaccine  type 2  candidate 1 (nOPV2 -c1) has been advanced into clinical development. The 
cDNA plasmid used to derive nOPV2- c1 was then further modified by [CONTACT_726842] (P1) 
region of the genome with the capsid from a Sabin- 1 (nOPV1) or Sabin- 3 (nOPV3) clone, generating 
chimeric viruses with novel type 2 non- structural regions coupled with Sabin- 1 or - 3 structural proteins.  
The nOPV study vaccines are named nOPV1 candidate 1 and nOPV3 candidate  1 (abbreviated nOPV1- c1 
and nOPV3- c1, respectively ). The use of the designation ‘ candidate 1’ is due to the potential subsequent 
development of additional candidate type -specific vaccines . For purposes of  simplification, in this protocol 
these study vaccines  will be referred to as nOPV1 and nOPV3, respectively.  
  
Table 1: G
enetic modifications of Sabin -2 in nOPV2 -c1 and their purposes.  
Modification  Purpose  
S15 dom V  -Improved stability of attenuated phenotype. 
Specifically, improve genetic stability of the domain V 
attenuating mutation to avoid reversion by [CONTACT_726852].  
-Lack of reversion may reduce shedding and 
transmission risk.  
Cre relocation   -Reduce frequency of recombination events. 
Specifically, a single recombination event replacing dom V will also remove cre, making virus non -viable 
and non -infectious.  
Polymerase  
(higher fidelity)  -Improved stability of attenuated phenotype. 
Specifically , improve fidelity of replication leading to 
less genetic drift and reversion.  
-Additional attenuation.  
Polymerase (rec)  -Reduce frequency of recombination events, thereby 
[CONTACT_726853].  
-Additional attenu ation.  
CVIA 076 – Version 5.[ADDRESS_992488] titers of less than 4. For nOPV1 and the Sabin- 1 
control, consistent positive responses were seen across the dos age range, with similar titers for the two 
at the higher dos ages. For type 3, nOPV 3 and the Sabin-3 control responses were similar across the full 
dosage range.  
As noted above, in this model seroconversion is dependent on replication; inactivated preparations are 
not immunogenic. Hence the immunogenicity, and by [CONTACT_726854], infectivity of these two nOPVs  was 
confirmed to be similar to  the Sabin controls. It is not suggested that this model reflects the environment 
of the human gut; however, the assay provides evidence that the candidates are phenotypi[INVESTIGATOR_726819] -[ADDRESS_992489] an improved risk profile as compared to the Sabin 
OPV strains. Regarding risk reduction, the following observations on the nOPV virus  seeds supporting this 
position were made:  
• Both nOPV1 and nOPV3 passed the WHO monkey neurovirulence test, with lower lesion scores than the reference controls and no paralysis of any monkeys. 
• In a transgenic mouse neurovirulence model, no dose of either nOPV  could be established that 
resulted in paralysis of any mice.  
• The temperature -sensitive phenotype, a marker for attenuation, was retained for both nOPV s. 
• Upon passaging in cell culture under conditions known to lead to reversion, both deep sequencing and mouse neurovirulence testing confirmed that the nOPVs  did not revert to any meaningful 
extent, while the Sabin strains showed clear reversion by [CONTACT_726855]. 
Incremental benefits of the polymerase modifications and cre relocation on genetic stability also were demonstrated using targeted experiments. 
In total, these results suggest that the potential risks associated with OPV use (VAPP and cVDPV 
circulation ) should be lower for nOPV1 and nOPV3 than for the Sabin comparators. This conclusion is 
further supported by [CONTACT_685679] p hase 1 and 2 clinical stud ies of the parental nOPV2 strain (from which 
these nOPVs  are derived) which demonstrated an absence of reversion of domain V and limited increases 
in virulence for shed virus  [9]. 
 Summary of Clinical Studies of Study Vaccine  
Although nOPV1 and nOPV3 have not previously been tested in humans,  two candidates of novel OPV2 
(nOPV2 -c1 and nOPV -c2) have been tested in three  clinical trials: p hase [ADDRESS_992490] of one of 
these vaccine candidates, nOPV2- c1, is very similar to nOPV1 and nOPV3, with the only difference being 
the type -specific capsid. For both p hase 2 studies, safety, immunogenicity, shedding and genetic stabilit y 
data were compared to data from studies performed 2 to 3 years prior with mOPV2 and designed to 
provide data for the comparison (historical control studies). Data for genetic stability in the pediatric study have not yet been finalized , but interim data are available from the young children in that study. A 
CVIA 076 – Version 5.[ADDRESS_992491] -in-human study was performed under containment at the University of Antwerp  [9]. Two 
cohorts of 15 adult participant s each were enrolled sequentially, with all participant s in each cohort 
receiving the same vaccine candidate (at a 106 CCID 50 dosage) to avoid cross -contamination between the 
two candidates  (nOPV2 -c1 and nOPV2- c2). All participant s had previously received at least 3 doses of IPV, 
and none had a history of receiving OPV (per eligibility criteria). The assignment of product to the cohorts 
was performed randomly, and neither study staff nor participant s were aware of which product was 
administered to which cohort. Containment of each cohort lasted until the last participant s in each had 
been in containment for [ADDRESS_992492].  
Phase 2 Study in Adults in Belgium  
The study was performed at two sites in Belgium (Antwerp and Ghent). The study population of healthy 
adults included 200 participant s who had previously received OPV (100 receiving nOPV2- c1 and 100 
receiving nOPV2-c 2, half of whom received a single dose (106 CCID 50) and the other half two doses) and 
another 50 who had previously received only IPV (17 receiving nOPV -c1, 16 receiving nOPV2-c 2 and 17 
receiving placebo). Participant s were sequentially enrolled, with completion of enrollment of those to 
receive nOPV2 -c2 (IPV and OPV groups simultaneously) before initiation o f enrollment of those to receive 
nOPV2 -c1 (IPV and OPV groups simultaneously). IPV -only vaccinated participant s were randomized 2:1 to 
receive one of the two vaccine candidates or placebo. Data from participant s who had previously received 
OPV were compared to those of a previous study, also in Belgium and similarly designed, in which 
previously OPV -vaccinated healthy adults were vaccinated with mOPV2.  
Phase 2 Study in Y oung Childre n a nd Infants in Panama  
This was a single -center, multi -site, age de- escalat ion, partly- randomized study performed in Panama. 
Two different cohorts of participant s were recruited: healthy young children enrolled and vaccinated at 1 
to 5 years of age and healthy infants enrolled at 6 weeks of age and vaccinated at 18- 22 weeks of ag e. 
Infants were recruited at 6 weeks of age to assure vaccination with 3 doses of bOPV and 1 dose of IPV 
prior to vaccination with nOPV2 at 18-22 weeks of age.  
The study was performed in two consecutive stages, Stage I and Stage II. In Stage I, young children and 
infants were vaccinated with nOPV2- c2 manufactured in 2016. In Stage II, young children and infants were 
vaccinated with nOPV2 -c1 and nOPV2- c2 manufactured in 2018. The difference between nOPV2- c2 
manufactured in 2016 and 2018 was the working virus seed used for each. Children received 106 
CCID 50/dose (high dose), and infants received either 105 CCID 50/dose (low dose) or 106 CCID 50/dose (high 
dose). All 1- 5 year old children were to receive two doses of vaccine, and a subset of 50 infants from each 
of the six groups were to receive two doses (the balance to receive a single dose). In Stage II, 49 1- 5 year 
old children were vaccinated with the high dose, 138 infants were vaccinated with the low dose , and 150 
infants were vaccinat ed with the high dose of nOPV2- c1. 
1.5.1 Safety  
The candidate vaccine, nOPV2- c1, was generally well -tolerated in all three studies. Safety data were 
reassuring, with overall safety profiles similar t o those of applicable control groups for the p hase 2 studies 
CVIA 076 – Version 5.0 
17 February  2022 
 
 28  (adults in Belgium, and 1- 5 year old children and 12- 22 week old infants in Panama). No SAE was  assessed 
as causally related to vaccine. Most solicited and unsolicited adverse events (AEs) were mild or moderate, 
and they were infrequently severe. No unsolicited severe AEs were assessed as related to vaccination in 
young children and infants, and no AEs resulted in termination from subsequent dosing (in those scheduled to receive two doses) or in w ithdrawal from the study.  
1.5.2 Immunogenicity  
In all three studies, nOPV2- c1 was immunogenic, and the immune responses were non- inferior to those 
following vaccination with mOPV2 in the historical control studies . 
1.5.3 Viral Shedding  
Results of stool testing for virus shedding generally indicate that nOPV2- c1 is not shed in a substantially 
greater rate or quantity as compared to mOPV2, and the rate of viral shedding is lower at four weeks 
following vaccination in a key demographic subgroup (bOPV/IPV -vaccinated infants ). 
1.5.4 Genetic Stability  
Genetic stability assessment of shed virus from the adult participant s in the p hase 1 and 2 studies in 
Belgium were consistent with improved genetic and phenotypic stability of the nOPV2 candidates. Interim results from 1 -5 year old children in the p hase 2 study in Panama are consistent with data from adults and 
show improved genetic  and phenotypic stability of nOPV2- c1; data from infants are pending. 
 Overall Development Strategy  
The objectives of the nOPV1,3 program are (1) to achieve licensure and World Health Organization (WHO) 
prequalification of novel OPV1 and OPV3 monovalent vaccines (nOPV1 and nOPV3) with an indication for active immunization against disease  caused by [CONTACT_726856] 1 or 3, respectively; (2) to provide 
sufficient evidence to support a policy decision to stockpi[INVESTIGATOR_726820], and (3) to potentially make nOPV1 and/or nOPV3 available pre -licensure during 
outbreaks, provided the early data demonstrate appropriate safety and immunogenicity. If  use of bivalent 
OPV (bOPV, which includes the Sabin type 1 and type 3 strains) continues for longer than anticipated, 
nOPV1 and nOPV3 could also be considered for routine use.
 
 HYPOTHESIS , OBJECTIVES AND ENDPOINTS  
 Study Hypotheses  
Safety  
• The live attenuated , novel  oral polio myelitis  vaccine  type 1 (nOPV1) is safe and well -tolerated in 
healthy adults  
• The live attenuated , novel  oral polio myelitis  vaccine  type 3 (nOPV3) is safe and well -tolerated in 
healthy adults  
Immunogenicity  
• nOPV1 and nOPV3 elicit demonstrable immune responses  in healthy adults  
CVIA 076 – Version 5.0 
17 February  2022 
 
 29  
 Study Objectives  
2.2.1 Primary Objective:    
Safety    
To evaluate the safety and tolerability of nOPV1 and nOPV3 in healthy adults  
2.2.2 Secondary Objectives:  
Immunogenicity  
To assess the humoral immune responses (neutralizing antibody titers ) elicited by [CONTACT_726844]1 and nOPV3, and 
compare to that of mOPV1 and mOPV3, respectively, in healthy adults  
Fecal Shedding of Study Vaccine  Virus es 
• To assess the duration of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3 after the 
initial dose and compare to  that of the homotypic mOPVs  
• To assess the rate of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3  and compare to 
that of the homotypic mOPVs  in participant s with an exclusive IPV prior vaccination histor y 
• To assess the extent of shedding (as determined by [CONTACT_726845]) of nOPV 1 and nOPV3 and 
compare to that of the homotypic mOPVs  in participant s with an exclusive IPV prior vaccination 
history  
2.2.3 Exploratory Objectives:  
• To assess the duration of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3 after the 
second dose and compare to  that of the homotypic mOPVs  
• To assess the rate of fecal shedding (as determined by [CONTACT_954]) of nOPV1 and nOPV3  and compare to 
that of the homotypic mOPVs  in participant s with an OPV-containing prior vaccination histor y 
• To assess the extent of shedding (as determined by [CONTACT_726857]) of nOPV1 and nOPV3 and 
compare to  that of the homotypic mOPVs in participant s with an O PV-containing prior vaccination 
history  
• To assess the potential for neurovirulence of nOPV shed virus as measured by a transgenic mouse 
neurovirulence assay, and compare to  that of mOPV1 and mOPV3  
• To as sess genetic stability of nOPV shed vaccine virus as determined by [CONTACT_077]  
• To assess the humoral immune responses elicited by [CONTACT_726844]1 and nOPV3 against non- vaccine 
poliovirus types  
 Study Endpoints  
2.3.1 Primary Endpoints:   
Safety  
• Frequency of serious adverse events (SAEs) from Day 1 study vaccination through the end of the 
study 
CVIA 076 – Version 5.0 
17 February  2022 
 
 30  • Frequency of solicited adverse events (AEs) for 7 days (day of study vaccination and 6 following 
days) after each dose of study vaccine 
• Frequenc y of unsolicited AEs for 28 days (day of study vaccination and 27 following days) after 
each dose of study vaccine [including clinically significant aberrant safety monitoring laboratory 
values on Day 8 reported as AEs] 
2.3.2 Secondary Endpoints:  
Immunogenicity  
• Median type -specific anti-polio serum neutralizing antibody titers  at baseline and post -
vaccination  
• Type -specific anti-polio serum neutralizing antibody Geometric Mean Titer ( GMT ) at baseline and 
post- vaccination  
• Post- vaccination GMT ratios of type -specific anti -polio serum neutralizing antibody, adjusted for 
baseline immunity  
• Post- vaccination frequency of any fold- rise (titer increased from baseline), a minimum 2 -fold rise, 
and a minimum 4- fold rise (seroconversion), in type -specific anti -polio serum neutralizing 
antibody response  
Fecal Shedding of Study Vaccine Virus es  
• Time to cessation of fecal shedding (days) of the vaccine virus, following initial dose  
• Proportion of participant s shedding type -specific vaccine virus at each post -vaccination stool 
collection , as assessed by [CONTACT_726858] s with an exclusive IPV prior vaccination history  
• Amount of vaccine virus in each stool sample (log 10 CCID 50 per gram) positive for virus (PCR)  in 
participant s with an exclusive IPV prior vaccination history  
• Shedding Index  of vaccine  virus shedding in stool, defined as the mean of log 10 CCID 50 per gram of 
stool at 7, 14, 21 and 28 days following each dose  in participant s with an exclusive IPV prior 
vaccination history 
• AUC of vaccine virus shed in stool  in participant s with an exclusive IPV prior vaccination history  
2.3.3 Exploratory Endpoints : 
• Time to cessation of fecal shedding (days) of the vaccine virus, following second  dose  
• Proportion of participant s shedding type -specific vaccine virus at each post -vaccination stool 
collection , as assessed by [CONTACT_726858] s with an OPV-containing prior vaccination history 
• Amount of vaccine virus in each stool sample (log 10 CCID 50 per gram) positive for virus (PCR)  in 
participant s with an OPV-containing prior vaccination history 
• Shedding Index  of vaccine virus shedding in stool, defined as the mean of log 10 CCID 50 per gram of 
stool at 7, 14, 21 and 28 days following each dose  in participant s with an O PV-containing prior 
vaccination history 
• AUC of vaccine virus shed in stool  in participant s with an O PV-containing prior vaccination histor y 
CVIA 076 – Version 5.0 
17 February  2022 
 
 31  • Neurovirulence of shed vaccine virus from select stool samples as measured by a transgenic 
mouse neurovirulence test  
• Deep sequencing of shed vaccine virus from select stool samples , using NGS  
• Serum neutralizing antibody titers against non- vaccine poliovirus types at baseline and post -
vaccination  
 STUDY DESIGN  
This multicenter trial is the first -in-human assessment of these novel oral poliomyelitis  vaccines. It will be 
an 8- arm, randomized, observer -blind, controlled trial, with Sabin monovalent vaccines serving as the 
control for each type (see study schema, below). 150 to 230 healthy, adult participant s will be recruited . 
30 to 40 of 60 to 80 participant s with an exclusive IPV prior vaccination history (cohort 1) will be 
randomized in a 1:1 ratio to study groups 1 and 2 and all ocated to receive nOPV1 or mOPV1, and once 
these study arms are completely accrued, the other 30 to 40 exclusively -IPV vaccinated participant s 
(cohort 3)  will be randomized in a 1:1 ratio to study groups 5 and 6 and allocated to receive nOPV 3 or 
mOPV 3. 
In parallel, 45 to 75 of 150 participant s with an OPV -containing prior vaccination history (cohort 2) will be 
randomized in a 2:1 ratio to study groups 3 and 4 and a llocated to receive two doses of nOPV1 or mOPV1, 
respectively, and once these study arms are completely accrued, the other 45 to 75 participant s with an 
OPV -containing prior vaccination history (cohort 4)  will be randomized in a 2 :[ADDRESS_992493] week of vaccination . Participant s will be followed until 24 
weeks  after the ir Day 1  study vaccination.  
Study Schema  
Cohort  Group  Prior 
Vaccination  Number of 
Participant s 
(Min -Max)  Dosage  
CCID 50  Day 1  Day 29  
        
1 1 IPV 15-20 106 5  nOPV1  - 
2 15-20 ≥106  mOPV1  - 
Subtotal    30-40     
2 3 OPV  30-50 106 5  nOPV1  nOPV1  
4 15-25 ≥106  mOPV1  mOPV1  
Subtotal    45-75     
3 5 IPV 15-20 106 5  nOPV3  - 
6 15-20 ≥105.8  mOPV3  - 
Subtotal    30-40     
4 7 OPV  30-50 106 5  nOPV3  nOPV3  
8 15-25 ≥105.8  mOPV3  mOPV3  
Subtotal    45-75     
Total    150-230     
 
CVIA 076 – Version 5.[ADDRESS_992494] been found to be eligible, randomized and vaccinated. Participant s withdrawn 
for any reason before vaccination will be replaced, participant s withdrawn for any reason after vaccination 
will not be replaced . Enrollment into the study will be competitive in that clinical sites will enroll as many 
subjects as they can, until the overall study enrollment goal is achieved; the total  number  of trial 
participants  enrolled  study- wide  does  not change . 
To be eligible for randomization and vaccination, participant s must meet all the inclusion criteria and none 
of the exclusion criteria for the study. The investigator should always use good clinical judgement in 
considering a participant ’s overall eligibility based on the inclusion and exclusion criteria.  
 Inclusion Criteria   
1. Males or females, from 18 to 45 years of age (inclusive) at the time of enrollment  
2. Healthy, as defined by [CONTACT_726859], either acute or 
chronic, as determined by [CONTACT_9870], physical examinatio n, screening  laboratory test results, 
and clinical assessment of the investigator  
3. Willing and able to provide written informed consent  prior to performance of any study- specific 
procedure  
4. If female and of childbearing potential *, be not breastfeeding and not pregnant (based on a 
negative serum pregnancy test at screening and a negative urine pregnancy test during the 24 hours prior to any study vaccination),  agreeing to have repeated pregnancy tests prior to any 
study vaccination , and having practiced  adequate contraception ** for [ADDRESS_992495] study vaccination  and until cessation of vaccine virus shedding is confirm ed 
* Females can be considered not of childbearing potential if they are with current bilateral tubal 
ligation , occlusion  or removal , or post -total hysterectomy, or post -bilateral ovariectomy  
** Adequate contraception is defined as a contraceptive method with failure rate of less than 
1% per year when used consistently and correctly and when applicable, in accordance with the product label, for example:  
• Abstinence from penile -vaginal intercourse  
• Combined estrogen and progesterone oral contraceptives  
• Hormonal (e.g., progestogen) injections  
• Hormonal (e.g., etonogestrel or levonorgestrel ) implants  
• Contraceptive vaginal ring 
• Percutaneous contraceptive patches  
• Intrauterine device  
• Intrauterine hormonal system  
• Male condom combined with a vagi nal spermicide (foam, gel, film, cream , or 
suppository), and/or progesterone alone oral contraceptive  
• Monogamous relationship with vasectomized ( ≥ 180 days prior to enrollment) partner  
CVIA 076 – Version 5.0 
17 February  2022 
 
 33  5. Resides in study area and is able and w illing to adhere to all  study restrictions and to all study 
visits and procedures  (as evidenced by a signed informed consent form [ICF] and assessment by 
[CONTACT_093] ) 
6. Agrees not to  and has no plans to  travel outside the [LOCATION_002] (US) until confirmation of 
cessation of vaccine virus shedding in stool at or after the study Day [ADDRESS_992496] telephone 
voice or electronic  messages as needed  
8. Neutralizing antibody titer ≥ 1:8 for poliovirus type 1 (for participants in cohorts 1 and 2) and ≥ 
1:8 for poliovi rus type 3 (for participants in cohorts 3 and 4)  
9. For Cohorts 1 and 3 only: p reviously received at least 3 doses of IPV  and with no history of receipt 
of OPV . For Cohorts 2 and 4 only: previously received a primary polio immunization series 
containing OPV  
 Exclusion Criteria  
1. Have any condition (medical, psychiatric or behavioral) that, in the opi[INVESTIGATOR_871] , 
would increase the participant ’s health risks in study participation or would increase the risk of 
not achieving the study’s objectives  (e.g., would compromise adherence to protocol requirements 
or interfere with planned safety and immunogenicity assessments)  
2. Receipt of polio vaccine within 12 m onths before the start of the study  
3. Having Crohn’s disease or ulcerative colitis or having had major surgery of the gastrointestinal tract involving significant loss or resection of the bowel  
4. A known allergy, hypersensitivity, or intolerance to any compone nts of the  study vaccines , 
including all macrolide and aminoglycoside antibiotics  (e.g., erythromycin and kanamycin)  
5. Any confirmed or suspected immunosuppressive or immunodeficiency condition (human immunodeficiency virus [HIV] infection, or total serum immunoglobulin A ( IgA) or immunoglobulin 
G (IgG ) level below the testing laboratory’s  lower limit of normal [LLN]) 
6. Administration of any long- acting immune -modifying drugs (e.g., infliximab or rituximab)  or the 
chronic administration (i.e., longer than 14 days) of immunosuppressant drugs (e.g., oral or 
systemic steroids) or other immune -modifying drugs within [ADDRESS_992497] vaccine 
dose or planned use during the study (inhaled and topi[INVESTIGATOR_726821] -
articular and epi[INVESTIGATOR_195037]/administration of steroids are not allowed)  
7. Will have household direct or close professional contact [CONTACT_726860] (due to underlying condition or treatments) or individuals  
who  have not yet complete d their primary infant polio immunization series  (i.e., three doses)   
8. Will have household direct  or close professional contact [CONTACT_726861] 
9. Will have  household direct or close professional (e.g., neonatal nurses) contact [CONTACT_726862]  2 years  of age  or with individuals who are encopretic (i.e., infants/toddlers 
who are not yet toilet trained or other individuals, including adults, with fecal incontinence)    
10. Will have p rofessional handling of food, catering, or food production activities during the st udy 
11. Reside in homes with septic tanks  
12. Acute illness or fever (body temperature measured orally ≥ 38°C or 100.4°F) at the time of study 
vaccine  administration (once acute illness/fever is resolved, if appropriate, as per investigator 
assessment, participant  may complete  screen ing) 
13. Indications of drug abuse or excessive use of alcohol  as deemed by [CONTACT_726863] 076 – Version 5.[ADDRESS_992498] (drug or vaccine) clinical trial within [ADDRESS_992499] administr ation of study vaccine, or planned use during the study 
period  
15. Administration of any vaccine  or any intramuscular injection (except seasonal inactivated 
influenza and COVID -19 vaccines  which are prohibited for only 14 days prior to or following each 
study vaccination) other than the study vaccine within [ADDRESS_992500] administration of study vaccine or planned use during the study  period  
17. Hepatitis B or C virus infection  
18. Any hematological# or chemistry ** parameter that is out of range of normal†† and is considered 
clinically significant by [CONTACT_093]  
#Complete blood count  (CBC) , includes  hemoglobin, hematocrit, white blood cell ( WBC ) count, 
neutrophil count, lymphocyte count, eosinophil count, and platelet count  
**Creatinine, alanine transaminase ( ALT), total  bilirubin  
††Per the site clinical laboratory’s reference ranges. All tests with out of range results that are regarded as clinically significant by [CONTACT_726864]. 
19. The following hematological or chemistry  laboratory results will be considered exclusionary, 
irrespective of assessment of clinical significance:  
Hemoglobin (Male) < 1 2.5 g/dL  
Hemoglobin (Female) < 11. 0 g/dL  
Neutrophil count < 1, 000 cells/mm
3 
Eosinophil count > 65 0 cells/mm3 
Platelet count < 1 25,000 cells/mm3 
Creatinine > 1.4 mg/dL  
ALT > 1.1 X Upper limit of normal (ULN) ††  
††Per the site clinical laboratory’s reference ra nges  
 STUDY PRODUCTS   
 Study  Vaccine  
5.1.[ADDRESS_992501] Description  
[IP_ADDRESS]  nOPV study vaccines 
Both nOPV s are live, attenuated poliovirus es derived from a modified Sabin type -2 infectious cDNA clone 
and propagated in Vero cells. Modifications were introduced in the viral nucleotide sequences in part of 
the 5ʹ  UTR to improve the genetic stability of this major attenuating determinant of Sabin type -2, and two 
modifications were made in the 3D polymerase to further improve stability of the attenuation and reduce 
recombination . In addition, a key replication element from the 2C coding region was relocated to the 5ʹ  
UTR to reduce the risk of loss o f stabilized 5’ UTR through recombination.  The cDNA plasmid was then 
further modified by [CONTACT_726842] (P1) region of the genome with the capsid from a Sabin- 1 
(nOPV1) or Sabin- 3 (nOPV3) clone, generating chimeric viruses with novel type 2 non- structural regions 
coupled with Sabin- 1 or - 3 structural proteins .  
CVIA 076 – Version 5.0 
17 February  2022 
 
 35  For th is study,  a 106.5 ± 0.5 CCID 50 dosage is planned for both nOPV1 and nOPV3. The dosage is considered 
likely to be similar to the actual dos ages of Sabin -1 and Sabin- 3 released by [CONTACT_8332], considering 
overages above the expi[INVESTIGATOR_726822] ( 106.0 and 105.8 CCID 50) for stability losses as well as process and 
analytical variability. Moreover, if in vitro  culture data suggesting a fitness reduction at 37oC compared to 
the homotypic Sabin strains transfers to human infectivity, this dosage allows a reasonable margin over 
the historical Sabin monovalent dosage known to be immunogenic ( 105.0 CCID 50 [10]) to have a reasonable 
expectation of responses. The safety of a [ADDRESS_992502] been studied at 107.0 CCID 50. 
[IP_ADDRESS]  Sabin mO P V control vaccines  
Both control vaccines are Sabin mOPV s that are constituent components of the WHO prequalified bivalent 
OPV manufactured by [CONTACT_726843]. Bio Farma also manufactures a WHO prequalified m OPV1 for 
supplemental campaigns. Both mOPV1 and mOPV3 will be manufactured and vialled by [CONTACT_726865]. 
In addition to the attenuate d poliovirus, the vaccine formulation includes sucrose and may contain trace 
amounts of not more than 2 mcg  erythromycin and not more  than 10 mcg  kanamycin . 
5.1.2 Manufacturer   
All vaccines to be used in this trial, both the nOPV study  vaccines and the Sabin mOPV control vaccines 
are manufactured by [CONTACT_726843], Indonesia.  
5.1.3 Presentation and  Formulation   
[IP_ADDRESS]  nOPV study  vaccines 
In addition to the attenuated poliovirus, the vaccine formulation includes sucrose, a cetic acid or NaHCO 3, 
and Basal Medium Eagle (BME) solution. The nOPV s are clear solutions, yello w to pi[INVESTIGATOR_136416] . The 
multidose vaccine vials (20 doses) contain approximately 2.2 mL of vaccine and are packaged with the 
dropper that is attached for administration directly from the vial. Each 0.1  mL (2 drops)  dose of vaccine 
contains approximately 106 5 CCID 50. In this study, only a single dose is to be administered from each 
multidose  vial provided.  
[IP_ADDRESS]  Sabin control vaccines  
The control vaccines are clear and light yellow to light red. The multidose vaccine vials (20 doses) contain 
approximately 2.2 m L of vaccine and are packaged with the dropper that is attached for administration 
directly from the vial. The mOPV1 control vaccine contain s >106.0 CCID 50 per 0.1 mL (2 drops) dose , and 
the mOPV3 control vaccine contains  >105.8 CCID 50 per 0.1 mL (2 drops) dose.  In this study, only a single 
dose is to be administered from each multidose vial provided. 
5.1.4 Stability and Storage  
Both nOPV s and Sa bin control mOPVs are to be transported and stored at ≤ -20oC and  thawed  prior to 
administration. Unopened vaccine vials may be thawed and kept at [ADDRESS_992503] not be 
refrozen . 
CVIA 076 – Version 5.[ADDRESS_992504] will affix the dropper to the vial and apply a n overlay on the vial o n which the participant  ID is 
printed, masking the identity of the contents of the vial. Study nOPV s and control mOPV s will be dispensed 
directly from the vials by [CONTACT_726866] 2 drops of study vaccine directly from the 
dropper into the participant ’s mouth.  To maintain the observer -blind study design, the se unblinded staff 
will not be involved in any o ther study assessments (e.g., safety assessments) of the participant s. Any 
vomiting following study vaccination during the post -vaccination observation period, including the precise 
time of the onset of vomiting, will also be recorded. There will be no vaccine redosing to compensate  for 
any vomited vaccine.  
 Accountability and D isposal  
The site pharmacist is required to maintain complete records of all study vaccines  received from PATH  
and will be responsible for maintaining an accurate record of the randomization codes, inventory, and an accountability record of vaccine s for this study.  The site pharmacist will also be responsible for ensuring 
the security of these documents.    Partially used vials will not be used for human administration or for in 
vitro experimental studies. At the end of the study, t he site will receive instruction from PATH  regarding 
the final disposition of any remaining study vaccines .   
 STUDY  PROCEDURES  
 Recruitment  
Study participant s will be recruited from the local community and reflect the demographics of the 
community yet keepi[INVESTIGATOR_726823] . The sites selected ha ve ample prior experience 
in the recruitment of healthy adult participant s from their local community for participation in preventive 
vaccine clinical trials. Information regarding this trial may be provided to potential participant s who have 
previously participated in vaccine trials conducted at the site. Other forms and mechanisms of recruitment may also be used. The local Institutional Review Board/Independent Ethics Committee (IRB/IEC ) will 
approve all materials prior to use. Careful recruitment and communication about all aspects of the study will be critical to ensu re eligible participant s who eventually participate in the trial are committed to 
participate for the full length of the study. It is anticipated that the sites selected  will recruit the requi red 
study sample size over a period of approximately sixteen  months.  
 Study Visits 
A schedule of study visits and evaluations for the participants with an exclusive IPV vaccination history 
(single dose  study groups)  and participant s with an OPV -containing vaccination history (two dose study 
groups ) can be found in Appendix 1.  
6.2.1 Screening – Day -90 to Day 1  
After the site Principal Investigator ( PI) or designee has obtained informed consent from participant s, the 
participant  will be considered enrolled, and the following procedures will be completed during screening 
to determine study eligibility and may occur over multiple screening visits. Additional screening visits may 
be scheduled for any follow up, as needed, but are not required. At the screening visit(s), the site PI [INVESTIGATOR_726824] s a detailed description of the study objectives and study 
CVIA 076 – Version 5.[ADDRESS_992505] vaccination . It is anticipated that it may  take up to 
two weeks to receive and evaluate all screening laboratory tests to confirm eligibility and allow for 
randomization. All inclusion/exclusion criteria must be assessed from data obtained within the screening  
period, unless otherwise specified in the eligibility criteria.  
After study information has been provided and the appropriate informed consent has been obtained, the 
following procedures are performed during the screening period before the Day 1 Visit : 
• Confirm written informed consent has been obtained and solicit/discuss any remaining 
ques tions the participant  may have  
• Assign participant  ID once study specific consent form has been signed 
• Obtain demographic and contact (e.g., address, telephone, email) information 
• Obtain medical history  
• Obtain history of prior COVID -19 vaccinations and ongo ing concomitant medication use  and any 
prior use  that impacts eligibility , including poliovirus vaccination history  (documented 
vaccination records is preferred; however, if not obtainable, to ascertain if vaccination history 
can be reasonably established by [CONTACT_726867] )  
• Measure height and  weight  
• Perform complete  physical examination  (including vital signs  [VS]) 
• Collect venous blood samples (approximately 45 mL) for 
o CBC, including hemoglobin, hematocrit, WBC count,  neutrophil count, lymphocyte count, 
eosinophil count,  and platelet count  
o Serum c hemistries to include creatinine, ALT, and total  bilirubin  
o Human immunodeficiency viruses 1 and 2 (HIV 1/2) infection testing  
o Hepatitis B virus surface antigen (HBsAg)  
o Hepatitis C virus antibody (HCV Ab) and if positive, HCV PCR  
o Total IgG  and total Ig A 
o Serum pregnancy test for females  of childbearing potential  (FOCB)  
o Neutralizing antibodies to type -specific polioviruses  (in addition to sample sent to  the 
Polio and Pi[INVESTIGATOR_726825], a sample will be sent to a 
commercial qualified laboratory , Quest Diagnostics , for screening purposes  [eligibility 
determination ] only 
 After confirmation of eligibility, participants can be randomized prior to Day 1.  
6.2.[ADDRESS_992506] Vaccination Visit  – Day 1  Visit  
Prior to Vaccine  Administration  
• Review concomitant medications  
• Review inclusion/exclusion criteria and ensure continued eligibility for study vaccination, including absence of symptoms that may confound later  safety and solicited AE assessments 
• If any interim symptoms, perform a targeted physical examination  
• Measure vital signs  
CVIA 076 – Version 5.0 
17 February  2022 
 
 38  • For females of childbearing potential (FOCB), assess and document continuing use of 
contraceptives  and p erform u rine pregnancy test  
• Collect venous blood samples (approximately 15 mL) f or 
o CBC, including hemoglobin, hematocrit, WBC count,  neutrophil count, lymphocyte count, 
eosinophil count, and platelet count  
o Serum chemistries to include creatinine, ALT, and total  bilirubin  
• If not done earlier than Day 1, o nce eligibility is confirmed , randomize participant  
Clinical safety laboratory test results used to determine participant eligibility will be those obtained at 
screening, but the Day [ADDRESS_992507] results will be used as baseline for analyses . 
Vaccine Administration  
• If an eligible  participant  is disqualified prior to study vaccine  administration (e.g., participant  
withdraws consent or the investigator  reconsiders and disqualifies for a documented reason), 
another eligible  participant  will be selected for randomization in place of the disqualif ied 
participant  
• The vaccine  will be administered  – 2 drops (0.1 mL ) by [CONTACT_726868] ’s dropper into the participant ’s mouth  
Post Vaccination  
• Observe participant  for at least [ADDRESS_992508] -vaccination  with medical treatment readily 
available in case of any immediate hypersensitivity reactions  
• Assess and document any interim adverse events, and if a participant  requires further on -site 
observation, additional site or clinical assessments may be completed as needed  
• Provide  participant  with supplies (including a thermometer and a memory aid) to record solicited 
AE information and instruct  the participant  in their use  
• Prior to discharge from the clinic, once the required observation period is over, the Day 1 solicited AE memory aid entries may be completed by [CONTACT_726869] 
• Provide participant s in Cohorts [ADDRESS_992509] a stool specimen within the appropriate windows 7 days after vaccination (study Day 8) , 
prior to their next scheduled visit . Cohorts [ADDRESS_992510] es, participants’ refusal 
to provide the additional stool sampling timepoints should not affect their eligibility to enroll into the study.  
• Provide participant  clear guidance on appropriate hygienic measures and supplies to minimize 
contact [CONTACT_726870] (e.g., collection kit, sanitizer, disinfectant, gloves)  and minimize risk of transmission of vaccine virus to others. As k participant  
to describe  these measures  (‘teach back method’ ) for hand washing and stool collection before 
leaving the clinic  and correct any errors  
• Provide participant  information about storage and transport of stool specimens to the study site  
• Schedule next study visit (Day 8 Visit) and i nstruct participant  to contact [CONTACT_726871], and irrespective, for any solicited AE defined greater than moderate in severity , and ensure participant  has appropriate contact [CONTACT_726872] m 
CVIA 076 – Version 5.0 
17 February  2022 
 
 39  • Once  all study related procedures are complete and the investigator  determines that the  
participant ’s condition is acceptable, the participant  may  be discharged from the study clinic   
6.2.3 Day 8 Visit , 7 (+1) days after the study vaccination – Clinic follow -up visit  
At the Day 8 Visit, the participant  will return to the study clinic for the following procedures:  
• Collect  any pending stool samples from the participant  
• Review with participant  the completed memory aid and ensure that the participant  has correctly 
interpreted the instructions in completing the memory a id; any required corrections to be clearly 
documented  
• Collect any new AEs since Day [ADDRESS_992511] not already been captured and review any AEs 
that are currently ongoing 
• Collect any new concomitant medications since Day [ADDRESS_992512] not already been captured 
and review any concomitant medications that are currently ongoing  
• If the participant  reports any intervening symptom or AE since the previous visit, perform a 
targeted physical examination, which is to include vital signs  
• Any topi[INVESTIGATOR_726826]  
• Collect venous blood samples (approximately 15 mL) for 
o CBC, including hemoglobin, hematocrit, WBC count,  neutrophil count, lymphocyte count, 
eosinophil count, and platelet count  
o Serum chemistries to include creatinine,  ALT, and total  bilirubin  
• Provide participants in Cohorts [ADDRESS_992513] stool specimens on study Days 15, 22, and 29 prior to their next scheduled visit . 
Cohorts 1 and 3 participants may contribute additional stool samples between study Days 8 and 29, in addition to the nominal study stool sampling days, if available. These optional samples will 
be used to increase the number of samples available for the exploratory genetic stability 
evaluation. Similar to future use samples, participants’ refusal to provide the additional stool 
sampling timepoints should not affect their eligibility to enroll into the study.  
• Provide participant  clear guidance on appropriate hygienic measures and supplies to minimize 
contact [CONTACT_726870] (e.g., collection kit, sanitizer, 
disinfectant, gloves)  and minimize risk of transmis sion of vaccine virus to others  
• Provide participant  information about storage and transport of stool specimens to the study site  
• Schedule next study visit (Day 29  Visit) and instruct participant  to contact [CONTACT_726871], and ensure participant  has appropriate contact [CONTACT_726873]  
6.2.4 Day 29 Visit , 28 (+2) days after the study vaccination – Clinic follow -up visit  
At the Day 29 Visit , the participant  will return to the study clinic for the following procedures:  
• Collect any pending stool samples from the participant  
• Collect any new AEs since Day [ADDRESS_992514] not already been captured and review any AEs 
that are currently ongoing 
• Collect any new concomitant medications since Day [ADDRESS_992515] not already been captured 
and review any concomitant medications that are currently ongoing  
CVIA 076 – Version 5.0 
17 February  2022 
 
 40  • If the participant  reports any intervening symptom or AE since the previous visit, perform a 
targeted physical examination, which is to include vital signs  
• Any topi[INVESTIGATOR_726827]  
• Collect venous blood sample (approximately 1 0 mL) for neutralizing antibodies to type -specific 
poliovirus es 
For participant s in Cohorts 1 or 3, who were  randomized to receive only a single  dose of study vaccine : 
• Provide participant  with instructions and supplies to collect stool specimens within the 
appropriate windows on study Days 3 6, 43, 50, and 57 prior to their next scheduled visit  
• Provide participant  clear guidance on appropriate hygienic measures and supplies to minimize 
contact [CONTACT_726870] (e.g., collection kit, sanitizer, 
disinfectant, gloves)  and minimize risk of transmission of vaccine virus to others. As k participant  
to describe  these  measures (‘teach back method’) for hand washing and stool collection before 
leaving the clinic and correct any errors  
• Provide participant  information about storage and transport of stool specimens to the study site  
• Schedule next study visit  (Day 169 Visit ), which will occur via telephone , and i nstruct participant  
to contact [CONTACT_726874]  
• Inform participant  that if  cessation of vaccine virus shedding is not confirmed  by [CONTACT_2006] [ADDRESS_992516] two scheduled stool samples, stool sample 
collection  duration for that participant  will be extended. As soon as the shedding results are known 
(anticipated approximately two  weeks after the last stool sample provided for evaluation) the participant  
will be asked to collect additional stool samples after the last per protocol sample  obtained over a period 
no shorter than [ADDRESS_992517] stool sample is missing the participant will be asked to provide a new sample as soon as possible 
in order to determine the need for furth er stool sample collection until poliovirus shedding is PCR negative 
on two consecutive stool samples.  
For participant s in Cohorts 2 or 4, who were  randomized to receive two doses  of study vaccine : 
• Review inclusion/exclusion criteria and ensure continued eligibility for study vaccination, including absence of symptoms that may confound later safety and solicited AE assessments  
• Measure vital signs  
• For females of childbearing potential (FOCB), assess and document continuing use of contraceptives an d perform u rine pregnancy test  
• If eligibility criteria are still met, 2 drops (0.1 m L) of study vaccine will be administered by 
[CONTACT_726875] ’s dropper into the participant ’s 
mouth  
• Observe participant  for at least [ADDRESS_992518]  vaccination with medical treatment readily 
available in case of any immediate hypersensitivity reactions  
CVIA 076 – Version 5.0 
17 February  2022 
 
 41  • Assess and document any interim adverse events, and if a participant  requires further on -site 
observation, additional site or clinical assessments may be completed as needed  
• Provide participant  with supplies (including a thermometer and a memory aid) to record solicited 
AE information and review its use again  
• Prior to discharge from the clinic, once the required observation period is over, the first day 
solicited AE memory aid entries may be completed by [CONTACT_726876] 
• Provide participant  with instructions and supplies to collect a stool specimen 7 days after second 
vaccination (study D ay 36) prior to the ir next scheduled visit  
• Provide participant  clear guidance on appropriate hygienic measures and supplies to minimize 
contact [CONTACT_726870] (e.g., collection kit, sanitizer, disinfectant, gloves)  and minimize risk of tr ansmis sion of vaccine virus to others  
• Provide participant  information about storage and transport of stool specimen to the study site  
• Schedule next study visit (Day 36  Visit) and instruct participant  to contact [CONTACT_726871], and irrespective, for any solicited AE defined greater than moderate in severity , and ensure participant  has appropriate contact [CONTACT_726872] m 
• Once all study related procedures are complete and the investigator determines that the participant ’s condition is acceptable, the participant  may be discharged from the study clinic  
6.2.5 Day 36 Visit , 7 (+1) days after the second study vaccination – Clinic follow -up visit  
Only for those in Cohorts [ADDRESS_992519] received a second study vaccination
 
 
At the Day 36 Visit, the participant  will return to the study clinic for the following procedures:  
• Review with participant  the completed memory aid and ensure that the participant  has correctly 
interpreted the instructions in completing the memory aid; any required corrections to be clearly 
documented  
• Collect any new AEs since Day [ADDRESS_992520] not already been captured and review any AEs 
that are currently ongoing 
• Collect any new concomitant medications since Day [ADDRESS_992521] not already been captured 
and review any concomitant medications that are currently ongoing  
• If the parti cipant  reports any intervening symptom or AE since the previous visit, perform a 
targeted physical examination, which is to include vital signs  
• Any topi[INVESTIGATOR_726828]  
• Provide participant  with instructions and supplies to collect stool specimens within the 
appropriate windows on study Days 43, 50, and 57 prior to the ir next scheduled visit 
• Provide participant  clear guidance on appropriate hygienic measures and supplies to minimize 
contact [CONTACT_726870] (e.g., collection kit, sanitizer, disinfectant, gloves)  and minimize risk of transmis sion of vaccine virus to others  
• Provide participant  information about storage and transport of stool specimens to the study site  
• Schedule next study visit (Day 57  Visit) and instruct participant  to contact [CONTACT_726871], and ensure participant  has appropriate conta ct details for the study team  
6.2.6 Day 57 Visit, 28  (+2) days after the  second  study vaccination – Clinic follow -up visit  
Only for those in Cohorts [ADDRESS_992522] received a second study vaccination  
CVIA 076 – Version 5.0 
17 February  2022 
 
 42   
At the Day 57 Visit, the participant  will return to the study clinic for the following procedures:  
• Collect any new AEs since Day [ADDRESS_992523] not already been captured and review any AEs 
that are currently ongoing 
• Collect any new concomitant medications since Day [ADDRESS_992524] not  already been captured 
and review any concomitant medications that are currently ongoing  
• If the participant  reports any intervening symptom or AE since the previous visit, perform a 
targeted physical examination, which is to include vital signs  
• Any topi[INVESTIGATOR_726826]  
• Collect venous blood sample (approximately 1 0 mL) for neutralizing antibodies to type -specific 
poliovirus es 
• Schedule next study visit (Day 169 Visit), which will occur via telephone  and i nstruct participant  
to contact [CONTACT_726874]  
• If cessation of vaccine virus sh edding has not been confirmed by [CONTACT_2006] [ADDRESS_992525] two scheduled stool samples, stool sample 
collection duration for that participant will be extended. As soon as the shedding results are known 
(anticipated approximately two weeks after the last stool sample provided for evaluation) the participant 
will be asked to collect additional stool samples after the last per protocol sample  obtained over a period 
no shorter th an [ADDRESS_992526] stool sample is missing the participant will be asked to provide a new sample as soon as possible 
in order to determine the need for further stool sample collection until poliovirus shedding is PCR negative 
on two consecutive stool samples.  
6.2.7 Day 169 Telephone Visit , 168 (+ 14) days after the initial study vaccination – Final Study 
Visit  
At Day 169, the participant  is expected to be available for a telephone follow -up for the following 
procedures:  
• Collect any new  SAEs reported since previous  Visit that have not already been captured and 
review SAEs that are currently ongoing 
• Collect any new SAE associated concomitant medications reported since previous  Visit that have 
not already been captured and review any SAE associated concomitant medications that are 
currently ongoing  
• Instruct participant to come to the clinic for a targeted physical exam, including vital signs, if they 
report any intervening symptom or AE since the previous visit that is of clinical concern  
CVIA 076 – Version 5.0 
17 February  2022 
 
 43  6.2.8 Unscheduled  Visits  
Unscheduled visits (those between regularly scheduled follow up visits) may be performed at participant  
request or as deemed necessary by [CONTACT_151913]. All unscheduled contacts 
and visits will be documented in the participant ’s study records and on applicable case report forms.   
 Discontinuation of Vaccination or S tudy Procedures  
Participant s have  the right to decline study vaccinations  or procedures for any reason and at any time 
during the study. If a participant  declines further vaccination or study procedures , this will be recorded as 
a study deviation and the reason will be clearly documented in the source document. The participant  will 
be encouraged to complete the  remaining applicable  safety related follow -ups and immunogenicity blood 
draw.  If the participant  does not wish to remain in the study by [CONTACT_726877] -up or procedures , 
the participant  can choose to withdraw consent and be withdrawn from the study . 
Discontinuation from further vaccination may be at the discretion of the i nvestigator  or Protocol Safety 
Review Team ( PSRT ), if determined to be in the participant ’s best interest to do so (e.g., safety concern) . 
In addition, participant s will be discontinued from further vaccination for the following reasons:  
• Pregnancy  
• Ineligibility (either arising during the trial or retrospectively having been overlooked at screening)  
• Significant or repeated non- compliance with trial requirements  
• An adverse event which requires discontinuation of study vaccination  or results in inability to continue 
to comply with trial procedures  
• Intercurrent illness or diseases or medical treatment that occur during the trial and might influence 
the study results or ability to continue to comply with trial procedures  
 Withdrawal from Study  
Participation in the study is strictly voluntary. Participant s have the right to withdraw from the study at 
any time and for any reason, without penalty. The investigator  or PATH  may, at their  discretion, withdraw 
a participant  from continuing in the study if  it is consider ed to be in the participant ’s best interest to do 
so, or if the participant  is not willing or able to comply with the study requirements. The reason for 
withdrawal will be documented in source document and relevant case report form ( CRF). 
In the event of withdrawal from study, reasonable efforts should be made to conduct the following procedures:  
• Review memory aid i f still in use prior to withdrawal  
• Updat e any ongoing AE/SAEs that remain ongoing at time of participant ’s last visit prior to withdrawal  
• Query about AEs /SAEs and concomitant medications if the interval between the participant ’s last visit 
and the time of withdrawal is within the protocol defined reporting period 
• Physical examination  including vital signs  
• Obtain any interim stool samples the participant  may have collected for the study  
• Collect venous b lood samples for safety laboratory testing if withdrawal occurs before Day 8 Visit, and 
for immunologic al testing if withdrawal occurs before Day 57 Visit 
• Update contact [CONTACT_726878], will be required to continue providing stool specimens for analysis and continue with requirements for mitigating the risk of fecal transmission until cessation of 
CVIA 076 – Version 5.[ADDRESS_992527] to follow -up. In addition, a  participant  who cannot be located 
or fails to respond after three  attempted contacts and has  missed two consecutive visits  (other than those 
scheduled primarily to provide stool samples)  will be considered lost to follow -up. Efforts to contact [CONTACT_726879].  There will be no replacement of participant s who 
are lost to follow -up.   
 Use of C oncomitant Medications  During the S tudy  
Prior to study start, participants will be encouraged to receive  Coronavirus  Disease 2019 ( COVID -19) 
vaccines , and receipt of COVID -[ADDRESS_992528] visit.  
Any medication (includes vaccines not administered as part of study ) administered to a participant  at any 
time between the Day [ADDRESS_992529] 
be recorded on source documents and the CRF with generic and/or trade name, indication, dosage, 
regimen, route of administration, and start and end dates. Betwe en the end of these periods and the final 
study visits only concomitant medications associated with an SAE  need to be recorded in the CRF . 
The following concomitant medications /vaccinations  are prohibited during the study; however, they must 
not be withheld by [CONTACT_726880] a participant  (e.g., response to 
epi[INVESTIGATOR_901], or post- exposure tetanus or rabies vacc ine prophylaxis):  
• Any investigational drug or vaccine  throughout the duration of the study  
• Any immunosuppressant or immune -modifying drug (includes systemic steroids) throughout the 
duration of the study  
• Any immunoglobulin or blood product through study Day 57  
• Any vaccine other than the study vaccines through study Day 57, which are prohibited for 30 days 
prior to or following each study vaccination (except for seasonal inactivated influenza and COVID -
19 vaccines, which are prohibited for only 14 days prior to or following each study vaccination)  
• Any intramuscular injection (except seasonal inactivated influenza and COVID -19 vaccines which 
are prohibited for only 14 days prior to or following each study vaccination) for 30 days prior to 
or following eac h study vaccination  
Note: Medication (e.g., antipyretic) should not be recommended prophylactically prior to study vaccine  
administration to prevent the onset of any post  study vaccine  administration symptoms, although may be 
administered after study vacci ne administration as clinically indicated.  
Use of any prohibited medication must be recorded in the CRF and as such participant ’s inclusion in the 
Per Protocol Population will be evaluated on a case by [CONTACT_413].  
CVIA 076 – Version 5.[ADDRESS_992530] that the blind be broken for the 
participant experiencing the emergency if knowledge of the participant’s study vaccine assignment may influence the participant’s clinical care. Prior to unblinding, the investigator is encouraged (to the extent possible, without jeopardizing the participant’s health) to contact [CONTACT_726881]. Unblinding will occur through the secure interactive web response system 
(IWRS), to which there will be 24- hour access. Documentation of the unblinding event will be captured by 
[CONTACT_8784]. The investigator will be expected to provide the rationale for the necessity of unblinding based 
on the reasonable expectation that knowledge of the participant’s treatment assignment will have a meaningful impact on the participant’s medical care in the short term. If a partic ipant’s treatment 
assignment is unblinded, the participant will remain in the study and continue with protocol -defined 
follow- up evaluations, including provision of biological samples, but will not receive further study 
vaccinations. The decision to unblind will be recorded in the participant’s study record and communicated 
to the IRB/IEC and other regulatory bodies, as required.  
 Management of B irth Control and P regnancy During Study  
Contraception status is assessed and documented prior to enrollment and each study visit  for female 
participant s who are of childbearing potential.  Prior to enrollment and at each vaccination  visit, staff will 
ask volunteers to  confirm their use of adequate contraception methods if they are able to become 
pregnant  and remind participant s about the need to continue using adequate contraception consistently 
for at least [ADDRESS_992531] study  visit will continue to be followed for pregnancy outcome, even if birth 
occurs after the scheduled end of the study for the participant , if possible.  The pregnancy and its outcome 
will be reported on the Pregnancy CRF.  
 Clinical Assessments  
Vital Signs  (VS) 
•  For vaccination visits, the site must measure oral temperature in degrees Celsius or Fahrenheit 
(recorded to the nearest 0.1 degree) using the same thermometer that will be used subsequently by 
[CONTACT_726882] -vaccination period for assessing 
reactogenicity . For all non -vaccination visits, sites may record temperature using any route (aural, 
axillary, tympanic, temporal, etc.), and document the method used.  
• Respi[INVESTIGATOR_726829] e.  
• Pulse rate in beats per minute will be measured by [CONTACT_519900]. 
• Non- invasive systolic and diastolic blood pressure will be measured in millimeters of mercury (Hg) by 
[CONTACT_519900].  
• Vital signs will be taken during all targeted physical exams  
Height and Weigh t 
• Height  will be  measured and recorded to the nearest c entimeter (cm) .  
CVIA 076 – Version 5.0 
17 February  2022 
 
 46  • Weight will be  measured in k ilogram (kg)  and recorded to the nearest 0.1 kg.  
Physical Examination  
Complete  physical examination will include assessment of vital signs, head, eyes, ears, nose, oropharynx, 
neck, respi[INVESTIGATOR_696]/pulmonary , cardiovascular, abdomen, musculoskeletal, lymph nodes (neck, 
supraclavicular, axillary, inguinal), extremities, skin, and neurolo gical.  
Targeted Physical Examination  
A focused physical examination based on any interim symptoms /AEs  reported by [CONTACT_2299] . 
Whenever  required, to always include an assessment of vital signs .  
Medical History  
A comprehensive medical history will be collected at screening, including details of any previous 
vaccinations in the past 30 days, any history of reaction s to vaccinations, participation in clinical trials  
(especially clinical trials of vaccines) , prior surgery  or hospi[INVESTIGATOR_059], allergy to food/drugs, current 
medication and history of any chronic or recurrent medical conditions. Detailed poliovirus vaccination 
history  to be collected , including requests t o review  poliovirus vaccination record s. If records not 
obtainable, to ascertain if vaccination history can be reasonably established by [CONTACT_726883].  
 LABORATORY EVALUATIONS /REQUIREMENTS  
 Sample Collection, Distribution and Storage  
Blood samples to evaluate vaccine safety will be obtained and processed at the clinical trial site and 
transported to each site’s designated laboratory for clinical testing.  
Serum specimens collected for assessment of immunogenicity will be separated into  aliquots per study 
specific process and stored at ≤ -20° C before being shipped to the Polio and Pi[INVESTIGATOR_726830] U nited States  Centers for Disease Control and Prevention (CDC).  For screening purposes 
(eligibility determination) only, a sample will be shipped to a commercial qualified laboratory , Quest 
Diagnostics . Samples will be stored in controlled -temperature freezers, with backup power supply to 
assure proper sample storage.  
Stool samples to assess presence of poliovirus and genetic stability of shed virus  will be processed at the 
clinical trial site in a Biosafety Level 2 (BSL -2) laboratory and stored at ≤-20°C before being transported to 
the Polio and Pi[INVESTIGATOR_726831] B.V., Rotterdam, The 
Netherlands . 
After either reference laboratory  (CDC or Viroclinics) completes  a successful test o n any serum or stool 
sampl e that has a back -up sample in storage, the laboratory  will destroy any of the remaining sample used 
for the testing within six  months.  
Details as to how blood and stool specimens should be  collected, processed, aliquoted, labeled, stored, 
and shipped will be provided in the study- specific Laboratory Manual.  
CVIA 076 – Version 5.0 
17 February  2022 
 
 47  
 Clinical Laboratory Tests 
Protocol mandated clinical  screening and safety laboratory tests will be conducted in real time  by [CONTACT_726884] a proficiency testing program.  These 
tests include:  
• CBC:  h emoglobin, hematocrit, WBC count, neutrophil count, lymphocyte count, eosinophil count, and 
platelet  count , performed at screening, and at Day 1 and Day 8 visit s 
• Serum Chemistry:  ALT,  total bilirubin,  and creatinine , performed at screening , and at Day 1 and Day 
8 visit s 
• Pregnancy test : Serum  β-HCG  at screening, then urine β- HCG  prior to each study vaccination  
(conducted on site)  
• Human immunodeficiency viruses 1 and 2 (H IV 1/2)  infection testing performed at screening  
• Hepatitis B  virus surface antigen performed at screening  (HBsAg) 
• Hepatitis C virus antibody ( HCV  Ab), if positive,  HCV PCR, performed at screening  
• Total IgG and IgA  performed at screening 
 
Laboratory results will be reviewed promptly by [CONTACT_093]. Participants will be notified of any 
clinically significant abnormalities. If clinically significant abnormalities are identified during screening, 
participants will be referred to their primary health provider or appropriate medical center. If identified 
during the study, participants may be asked to return to the study site for further evaluation, including 
clinical evaluation and repeat laboratory testing (e.g., monitoring for resolution or stabilization) as warranted. Any test may be repeated for test results determined to be spurious by [CONTACT_093] (e.g., following improper specimen collection) or if a valid test cannot be performed on the original blood collected (e.g., collection tube broken during transportation).  
 
The immunological assays to be performed include :  
• Serum neutralizing antibodies to type -specific  poliovirus es at screening and 28 days after each vaccine 
dose, to be performed at 
the Polio and Pi[INVESTIGATOR_726825] (for screening 
purposes [eligibility determination] only, baseline assays will be performed at a commercial qualified 
laboratory , Quest Diagnostics ) 
 Assessment of S hed Poliovirus  
• Multiplex real- time PCR  for identification of type -specific  poliovirus in stool , to be performed at the 
Polio and Pi[INVESTIGATOR_726825]  
• CCID 50 for quantification of type 1 or 3 poliovirus in stool, to be performed at the Polio and 
Pi[INVESTIGATOR_726825]  
• Quantitative PCR for quantification of type 1 or 3 poliovirus in stool  may be performed at Viroclinics 
Biosciences B.V.  
• Neurovirulence of fecally shed vaccine virus as assessed by a transgenic mouse neurovirulence test (TgmNVT), to be performed at Viroclinics Biosciences B.V.  
• NGS of fecally shed vaccine virus, to be performed by [CONTACT_726885] B.V.  
The operational definition of cessation of vaccine virus shedding in stool is  2 consecutive stool  
specimens  determined to be negative by [CONTACT_726886] a period no shorter than 24 hours .  
CVIA 076 – Version 5.0 
17 February  2022 
 
 48  
 Future Use of S tored Samples  
Participant s will be informed about and asked whether they agree to the long- term  storage of the ir 
biological (stool and serum) specimens for u se in future research as part of the informed consent process.  
Participant s need not agree to this long- term storage component of the study to otherwise be consented 
to take part in the study.  Participant s who do agree to this will be  consenting to the indefinite long- term 
storage of their remaining biological samples and data for use in future research, which unless further 
consent and IRB/IEC approvals are obtained, will be restricted to further knowledge about polio, the study  
vaccine s, immune responses to the study vaccine s, and the development of assays to measure these 
immune responses. No tests will be performed on the participant’s genome. At study closure, thes e 
additional remaining samples will continue to be stored at the Polio and Pi[INVESTIGATOR_726832] , and/ or if required , another PATH -designated biorepository that meets all current poliovirus 
containment requirements . 
 Biohazard Containment  
As transmission of blood -borne pathogens can occur through contact [CONTACT_83176], blood, 
and blood products, appropriate blood and secretion precautions will be employed by [CONTACT_573940][INVESTIGATOR_726833]. 
Risk mitigation procedures for the prevention of transmission of shed vaccine poliovirus during the collection, processing, storage , and transport of stool specimens will also follow CDC guidel ines as stated 
in this protocol and  detailed in the study- specific Laboratory Manual.  All biological specimens will be 
transported using packaging mandated by [CONTACT_726887] ( CFR) [ADDRESS_992532] be transported according to instructions detailed in the International Air Transport Association (IATA) Dangerous Goods Regulations. Biohazardous waste will be contained according to institutional, transportation/carrier, and all other applicable regulations.   
All protocol specimens will be shipped using packing that meets requirements specified by [CONTACT_726888] 3373, B iological Substan ce, 
Category B, and Packing Instruction 650.  Culture isolates, if obtained in this study, are to be shipped as 
specified for UN 2814 Category A Infectious Substances.  
 SAFETY ASSESSMENT AND REPORTING 
 Definitions  
8.1.1 Adverse Event (AE)  
An adverse event (AE) is any untoward medical occurrence in a participant  after administration of the 
study vaccine  and that does not necessarily have  a causal relationship with the study vaccine. An AE can 
therefore be any unfavorable and unintended sign ( including clinically significant abnormal laboratory 
finding), symptom, physical examination, or disease temporally associated with the use of the study vaccine, whether or not related to the study  vaccine.  This definition includes exacerbations of pre -existing 
conditions.  Stable pre -existing conditions that  do not change in nature or severity during the study are 
not considered AEs; however,  these should be reported as part of the medical history.  
Solicited AEs  are pre -specific AEs that are common or known to be associat ed with vaccination that are 
actively monitored as potential indicators of vaccine reactogenicity. Investigators will not be required to 
CVIA 076 – Version 5.[ADDRESS_992533] beyond the 
solicitation period  will continue to be captured as solicited AEs.  
The following specific solicited AEs will be monitored for this trial  (Cohort 1) : 
• Fever (oral temperature ≥ 38.0°C or 100.4°F) . (The temperature comparison table with the 
different methods used can be found in the study MOP .) 
• Chills  
• Fatigue  
• Headache  
• Muscle aches/Myalgia s 
• Joint ache s/Arthralgia s 
• Nausea  
• Vomiting  
• Abdominal pain 
• Diarrhea  
The following specific solicited AEs  will be monitored for this trial (F Cohorts 2 and 3) : 
• Fever ( axillary  temperature ≥ 3 7.5°C)  
• Vomiting  
• Diarrhea  
• Irritability  
• Decreased feeding  
• Decreased activity  
Unsolicited AEs  are any AEs reported spontaneously by [CONTACT_2299] , observed by [CONTACT_696691] . 
In the absence of a diagnosis, abnormal physical examination findings or abnormal clinical safety 
laboratory test results that are assessed by [CONTACT_726889].  
8.1.2 Adverse reaction  / Suspected Adverse Rea ction (21CFR Part 312.32) 
Suspected adverse reaction  is any adverse event for which there is a reasonable possibility that the 
vaccine caused the adverse event. For the purposes of IND safety reporting, "reasonable possibility" 
means there is evidence to suggest a causal relationship between the vaccine  and the adverse event. 
Suspected adverse reaction implies less  certainty about causality than adverse reaction, which means any 
adverse event caused by a vaccine . 
Adverse reaction  is any adverse event caused by [CONTACT_29500].  Adverse reactions  are a subset of suspected 
adverse reaction s for which there is reason to conclude that the vaccine  caused the event.  
Unexpected adverse event or unexpected suspected adverse reaction  refers to an event or rea ction that 
is not listed in the IB or is not listed at the specificity or severity that has been observed.  
CVIA 076 – Version 5.0 
17 February  2022 
 
 50  8.1.3 Serious Adverse Event  (SAE)   
Serious adverse event is any adverse event that results in any of the following outcomes : 
• Death  
• Is life-threatening ( life-threatening means that the study participant  was, in the opi[INVESTIGATOR_726834] , at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe)  
• Requires i npatient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions  
• Congenital anomaly  or birth defect  
• Important medical event that  may not result in one of the above outcomes , but based upon 
appropriate medical judgment , may jeopardize the health of the study participant , and require 
medical or surgical intervention to prevent one of the outcomes listed  above   
Suspected unexpected serious adverse reaction  (S[LOCATION_003]R)  is any suspected adverse reaction that is both 
unexpected and serious . 
 Reporting Period and Parameter  
Safety events are reported from the time of signing the ICF through each participant ’s completion of the 
study 168 days  after the ir Day 1 study vaccination.  Specifically , solicited AEs will be  collected  for 7 days 
(day of study vaccination and 6 following days) after each dose of study vaccine . If a solicited AE started 
during the [ADDRESS_992534] -vaccination and continues  beyond the 7 days,  it will continue to be reported as a 
solicited AE . Unsolicited AEs will be  collected for 28 days (day of study vaccination and 27 following days) 
after each dose of study vaccine . SAEs will be collected  from Day 1 study vaccination through the end of 
the study (Day 169 Telephone visit). 
Any untoward medical occurrence after signing the ICF but before receipt of study vaccine, although not 
to be reported as an AE, if it is assessed as related to participation in the study, must still be reported  by 
[CONTACT_726890] [ADDRESS_992535] is unable to come to the clinic for a visit, the scheduled and applicable safety assessments may  be 
conducted by [CONTACT_756].  
 
 Severity of Adverse Event s 
Solicited AEs:  
The severity of all solicited AEs will be graded based on the grading scale in Table 4 below.  
Table 4: Grading scale to grade the severity of solicited AEs 
Solicited AE  Grade  Definition  
   
Fever  
(oral body temperature)  0 < 100.4°F (none)  
1 ≥ 100.4°F to < 101.5°F  
2 ≥ 101.5°F to < 102.7°F  
3 ≥ 102.7°F  
CVIA 076 – Version 5.0 
17 February  2022 
 
 51  Diarrhea  0 None  
1 2 to 3 loose stools per 24 hours  
2 4 to 5 stools per 24 hours  
3 6 or more watery stools per 24 hours  
Chills or fatigue or 
headache or myalgias 
or arthralgias or nausea or vomiting or abdominal pain 0 None  
1 Causes no or minimal interference with usual social & functional 
activities  
2 Causes greater than minimal interference with but does not prevent 
usual social & functional activities  
3 Causes inability to perform usual social & functional activities  
 
Abnormal clinical safety laboratory test results reported as AEs:  
The severity of abnormal clinical safety laboratory test results reported as AEs  will be graded based on 
the grading scale in Table 5 below . The table is adapted from the FDA Guidance for Industry: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials 
(September 2007). In the absence of a diagnosis, a ny clinical safety laboratory test result that meets the 
definition of an SAE  as determined by [CONTACT_093]  (e.g., life -threatening) must be reported as an SAE. 
Table 5: Grading scale to grade the severity of abnormal clinical safety laboratory test results 
reported as AEs  
Parameter  Grade 1 (Mild)  Grade 2 (Moderate)  Grade 3 (Severe)  
    
Hemoglobin [Female] (g/dL)  11.0 – 12.0  9.5 – 10.9  < 9.5  
Hemoglobin [Female] change from 
baseline value (g/dL)  Any decrease – 1.5 1.6 – 2.0 > 2.0  
Hemoglobin [Male] (g/dL)  12.5 – 13.5  10.5 – 12.4  < 10.5  
Hemoglobin [Male] change from 
baseline value (g/dL)  Any decrease – 1.5 1.6 – 2.0 > 2.0  
WBC Increase (cell/mm3) 10,800 – 15,000  15,001 – 20,000  > 20,000  
WBC Decrease (cell/mm3) 2,500 – 3,500  1,500 – 2,499  < 1,500  
Lymphocytes Decrease (cell/mm3) 750 – 1,000  500 – 749 < 500  
Neutrophils Decrease (cell/mm3) 1,500 – 2,000  1,000 – 1,499  < 1,000  
Eosinophils (cell/mm3) 650 – 1,500  1,501 – 5,000  > 5,000  
Platelets Decreased (cell/mm3) 125,000 – 140,000  100,000 – 124,000  < 100,000  
Creatinine (mg/dL)  1.5 – 1.7 1.8 – 2.0 > 2.0  
ALT increase by [CONTACT_12245]  1.1 – 2.[ADDRESS_992536]*  > 2.5 – 5.[ADDRESS_992537]*  > 5.[ADDRESS_992538]*  
Total bilirubin increase by [CONTACT_12245]  1.1 – 1.[ADDRESS_992539]*  > 1.5 – 2.[ADDRESS_992540]*  > 2.[ADDRESS_992541]*  
*ULN = upper limit of normal  
Other AEs : 
The severity of all AEs  other than solicited AEs  and abnormal clinical safety laboratory test results reported 
as AEs  will be assessed by [CONTACT_726891]  (as applicable) based on the Division of AIDS 
(DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, corrected version 2.1, July 2017, of the US National Institute of Health, a vailable from:  
CVIA 076 – Version 5.0 
17 February  2022 
 
 52   https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf  
The severity grading criteria provided grade AEs from m ild (grade 1) to li fe threatening (grade 4). All AEs 
leading to death are Grade [ADDRESS_992542] severity grade during the 
illness/symptoms.  Life threatening events and events leading to death must be reported as SAEs.  
 Causality of Adverse Event   
The s tudy investigators will determine the causal relationship between the study vaccine  and the AE.  The 
causality assessment is made based on  the available information at the time of reporting and can be 
subsequently changed according to follow -up information.  Assessment  of causality is  based  on clinical 
judgment and should take into consideration the following factors:  
• Is there a temporal rel ationship between the event and administration of the study vaccine ? 
• Is there a plausible biological mechanism for the study vaccine to cause the AE?  
• Is there a possible alternative etiology for the AE such as concurrent illness, concomitant medications?   
• Are there previous reports of similar AEs associated with the study vaccine  or other vaccines in the 
same class?  
For this study, the investigator must classify the causality of the AE according to the categories defined 
below:   
Related : There is a reasonable possibility that the study vaccine  caused the event . “Reasonable possibility” 
means that there is evidence to suggest a causal relationship between the study vaccine  and the AE.  
Not Related : There is not a reasonable possibility that the administration of the study vaccine  caused the 
event.  
 Follow -up of Adverse Event  
All reported AEs should be followed until resolution or stabilization, or until the participant ’s participation 
in the study ends. The investigator must ensure that any AEs that are ongoing at study completion have 
been appropria tely referred to the local health care system for continuation of care . Participant s who 
have an ongoing study vaccine related SAE at study completion or at discontinuation from the study will 
be followed by [CONTACT_726892], chronic, or 
stable by [CONTACT_093] . 
The outcome of adverse event s will be assessed at the time of last observation as per the following 
categories:  
• Recovered/resolved without sequelae  
• Reco vered/resolved with sequelae  
• Recovering /resolving  
• Not recovered/not resolved  
• Fatal  
• Unknown.  The outcome of the AE is not known 
Due to uncertainties around the COVID -[ADDRESS_992543] of care diagnostic testing and if needed, a quarantine period for SARS -
CoV-2. 
CVIA 076 – Version 5.0 
17 February  2022 
 
 53  
 General Guidance on Recording Adverse Event s  
To improve the quality and precision of acquired AE data, the investigator  should observe the following 
guidelines:  
• AEs must be assessed for sev erity (graded) and causality and reviewed by [CONTACT_617843] . 
• If an AE (e.g., low hemoglobin) meets the criteria for two different severity grades simultaneously 
(e.g., Grade 1 for absolute hemoglobin level and Grade 2 for change from baseline value) , the severity 
grade reported should be the most severe grade (i.e., Grade 2 in the  example provided) . 
• Whenever possible, use recognized medical terms when recording AEs on the AE CRF. Do not use colloquialisms or abbreviations.  
• If known, re cord the diagnosis (i.e., disease or syndrome) rather than component signs, symptoms 
and laboratory values (e.g., record congestive heart failure rather than dyspnea, rales, and cyanosis) ; 
however signs and symptoms that are considered unrelated to an encountered syndrome or disease 
should be recorded as individual AEs (e.g., if congestive heart failure and severe headache are observed at the same time, each event should be recorded as an individual AE).  
• AEs occurring secondary to other events (e.g., sequelae) should be identified by [CONTACT_86187]. A “primary” AE, if clearly identifiable, generally represents the most accurate clinical term to record.  If 
a primary serious AE (SAE) is recorded, events occurring secondary to the primary event should be 
described in the narrative description of the case.  For example:  
Orthostatic hypotension  ®   Fainting and fall to floor  ®   Head trauma®    Neck pain  
The primary AE is orthostatic hypotension.  
• Death is an outcome of an event. The event that resulted in the death should be recorded and reported on the SAE CRF.  
• For hospi[INVESTIGATOR_304867], the illness leading to the surgical or 
diagnostic procedure should be recorded as the SAE, not the procedure itself. The procedure should 
be captured in the case narrative as part of the action taken in response to the illness.  
• Pregnancies that occur in study participant s are not considered AEs and will be recorded on a separate 
Pregnancy CRF. Pregnancy outcomes that include spontaneous abortion, stillbirth or any congenital 
anomal y must be reported as SAEs.  
 Reporting of SAE s 
PATH  has designate d Emmes  with authority to coordinate SAE reporting activities. All SAEs which occur 
during the study, whether considered to be associated with the study vaccine or not, must be reported within 24 hours of the site becoming aware of the event to the Emmes Medical Monitor  by [CONTACT_726893] (e.g., electronic data capture [EDC] system, email, or fax). Contact [CONTACT_726894] a handout located in the Investigator Site File. If the 
SAE is fatal or life -threatening, the study medical monitor shall be informed im mediately by [CONTACT_6968] .  
The investigator should not wait for additional information to fully document the event before notifying Emmes . When additional information becomes available, follow -up submissions will be submitted. The 
initial SAE form should be comp leted with all information known at the time and should include minimal 
elements for initial assessment : 
• Name [CONTACT_3669] [CONTACT_726895]  
• Participant  ID number  
• Date participant  received study vaccine   
CVIA 076 – Version 5.0 
17 February  2022 
 
 54  • Description of the SAE and date of event onset  
• Investigator’s preliminary assessment of severity and causality  
Whe n applicable, hospi[INVESTIGATOR_117984]  (without name [CONTACT_726928] ). 
The investigator is also r esponsible for reporting all SAEs to their IRB /IEC in accordance with institutional 
policy and adequate documentation of this reporting must be provided to Emmes . 
Reporting procedures for all SAEs will be followed as per FDA regulatory guidelines.  The stud y Safety 
Management Plan (SMP) will contain all the details of safety and regulatory reporting. Emmes is 
responsible for safety  reporting to the FDA within the following time periods : 
• Serious and unexpected suspected adverse reaction within 15 days of awareness  
• Fatal or life -threatening suspected adverse reaction within 7 days of awareness  
 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or site SOP requirements. 
The noncompliance may be either on the part of the participant , the PI, or the study site staff. As per ICH 
E6(R2), t he investigator must not deviate  from the protocol unless it is required to eliminate an immediate 
hazard to a trial participant . If required, as soon as is possible, the implemented deviation  and the reason 
for it  should be submitted to the IRB/IEC and PATH and a determination made as t o whether a protocol 
amendment is required.  
Deviations can be categorized as either major or minor. Reporting requirements of deviations depend on the type or degree of deviation. The procedures for handling protocol deviations will occur as follows: The PI [INVESTIGATOR_726835].  
The timeline for reporting protocol deviations to the IRB and PATH is determined by [CONTACT_726896]. Major protocol deviations are a subset of protocol deviations that may 
significantly impact the completeness, accuracy, or reliability of the study data or that may significantly 
affect a participant 's rights, safety, or well -being. For example, major protocol deviations may include 
failure to obtain informed consent, failure to report SAEs, enrolling participant s in violation of key 
eligibility criteria designed to ensure a specific participant  population or failing to collect data necessary 
to interpret p rimary endpoints, as this may compromise the scientific value of the trial . Major deviations 
that occur in this protocol will be reported to PATH  in an expedited manner (within 48 hours) and  to the 
IRB/IEC  as per their stated requirements.  
Minor deviations  are departures from the protocol that do not involve participant  safety or integrity of 
the study data.  Minor deviations will be reported to the IRB /IEC in the context of  the annual  Continuing 
Review Report  or as per their stated requirements if any diffe rent. Major deviations should also be 
summarized in the continuing review reports. 
Knowledge of any instances of serious or continuing non-com pliance with the regulations or requirements 
will be reported immediately to PATH  and the IRB /IEC.  
CVIA 076 – Version 5.0 
17 February  2022 
 
 55  
 SAFETY  OVERSIGHT  
The site PIs and designated site staff will be responsible for continuous close safety monitoring of all study 
participant s and for alerting PATH  if unexpected concerns arise or once aware that any study pause criteria 
are met.   
 Routine Reviews by [CONTACT_726840]  (PSRT)  
The Protocol Safety Review Team (PSRT), comp osed of the site PIs, the PATH  Medical Officer and Emmes  
medical monitor, will routinely monitor safety throughout the duration of the trial. The PSRT will be chaired by [CONTACT_726897][INVESTIGATOR_726836], including referral to the IDMC , part icularly for consideration of unblinded review. The 
Emmes  statistician , with assistance of the data management staff , will prepare  blinded safety reports for 
review by [CONTACT_111153].  These reports will provide at a minimum the following information:  
• accrual and participant  status data regarding completion of study vaccinations  and study visits   
• summar ies of solicited , unsolicited , and serious  adverse events  
• predefined abnormal  safety lab oratory test results 
• updated medical history and concomitant medi cation listings  
The PSRT safety review will be conducted by [CONTACT_577] (or electronically when appropriat e) 
occurring at least once monthly until all participant s have completed their Day [ADDRESS_992544] study integrity and participant safety. These may include , but are 
not limited to , data quality, critical monitoring findings, study vaccine  concerns , and issues with research 
specimens.  Emmes will also notify the PSRT of the need for  ad hoc safety reviews whenever it is aware 
of a S[LOCATION_003]R or adverse events that meet pre- specified study pause criteria as  per section 9.3. 
 Independent Data Monitoring Committee ( IDMC ) Reviews          
An IDMC  composed of at least three independent members with expertise in vaccine clinical trials will be 
convened by [CONTACT_726898]. The responsibilities and 
procedures of the IDMC are defined in the IDMC Charter.  
The IDMC will convene for an organizational meeting prior to study initiation and then for at least three  
scheduled meetings during the conduct of the study.  For each of the two nOPV types, one meeting will 
be scheduled once [ADDRESS_992545] will notify the responsible 
IRB/IEC  expeditiously. 
 Study Pause Rules 
The following study pause rules will automatically halt any further study vaccinations ; however , 
participant s already vaccinated  will continue to be followed for safety during the pause. These pause rules 
CVIA 076 – Version 5.[ADDRESS_992546] of the study:  
• One or more participant s experience an SAE that cannot reasonably be attributed to a cause other 
than study vaccine  
• Three or more participant s experience  the same severe (grade 3) solicited AE  within 7 days following 
study vaccination  that cannot reasonably be attributed to a cause other than study vaccine  
• Three or more participant s experience the same severe ( grade 3) unsolicited AE ( including laboratory 
abnormality ) within [ADDRESS_992547] become aware that a pause rule  has been met, they will inform Emmes  
immediately. Emmes  will cease randomization and notify the site PIs that a pause rule has been met and 
that no further enrollment should occur,  and no  study vaccin es are to be administered until specific 
notification is provided that study vaccinations can resume.  
As soon as it is confirmed that a study pause rule has been met, t he IDMC  will be notified and will 
expeditiously (within 48 hours , if possible ) convene  by [CONTACT_726899], relevant 
information , including initial exclusive access to unblinded data. The IDMC  reviews will be summarized 
with recommendations  to PATH  as to whether there are safety concerns and whether the study should 
continue without change, be modified, or be stopped. 
If at any time, a decision is made to permanently discontinue administration of study vaccine  in all 
participant s, notification will be provided by [CONTACT_726900] [INVESTIGATOR_27365] /IEC within 48 hours . 
If PATH  re-starts the study after IDMC  review and recommendation, enrollment and study vaccination 
may resume. The PI s will report the study pause and decision to resume to the ir IRB/IEC.  
 DATA HANDLING  and RECORDKEEPI[INVESTIGATOR_726837], legible, attributable, 
accurate, and recorded in a timely manner. Data collection is the responsibility of the  site clinical trial staff 
under the supervision of the site PI.  All source documents and laboratory reports must be reviewed by 
[CONTACT_726901], who will ensure that they are accurate and complete.  
Emmes  is responsible, under oversight of PATH, for data management activities, including quality review, 
analysis, and reporting of the study data according to Standard Operating Procedures ( SOPs ). 
 Definitions  
10.1.1  Source Data  
All information in origi nal records and certified copi[INVESTIGATOR_615852], observations, 
or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data 
are contained in source documents (original records o r certified copi[INVESTIGATOR_014] ; ICH E6 [R2] section 1.51) . 
CVIA 076 – Version 5.0 
17 February  2022 
 
 57  10.1.2  Source Documents  
Original documents, data and records (e.g., hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda, participant s' diaries of evaluation checklists, pharmacy dispensing records, recorded data 
from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x -rays, participant  files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved in the 
clinical trial (ICH E6 [R2] section 1.52) . 
 Data Capture Methods  (Case Report Form Development and Completion)  
The clinical data in source documents will be entered directly  into a 21 CFR Part 11- compliant EDC system 
by [CONTACT_726902]. The electronic CRF  (eCRF) for the EDC system will be developed by 
[CONTACT_726903] . Clinical data for 
each participant  will be entered directl y into the eCRF  from the source documents.  
It is the site PIs’ responsibility to ensure the accuracy, completeness, and timeliness of the data reported 
in the participant ’s eCRF and any supporting documentation. All source documents should be completed 
in a neat, legible manner to ensure accurate interpretation of data. Source documentation supporting the 
eCRF data should document the dates and details of study procedures, AEs and participant  status. The 
site PIs/institutions will maintain all information in the eCRFs and all source documents that su pport the 
data collected from each participant  in a secure area and treated as confidential material.     
 Data Management  
A thorough Data Management Plan and corresponding database compliant with ICH requirements will be 
developed b y Emmes Data Management  (DM) . Emmes  DM will build, validate , and maintain a Good 
Clinical Practice ( GCP) compliant EDC system.  The data system will include password protection and 
internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Write access to the system will be limited to authorized Investigators  and study 
staff, and the system will automatically keep an audit trail of all entries and corrections in the eCRF.  
Emmes  DM will perform all activities as per their SOPs, and in accordance with PATH SOPs. Coding of 
medical history and adverse events will be performed using the latest version of MedDRA. Medications 
will be coded using the latest World Health Organization Drug Dictionary. The eCRFs and any supporting 
documentation should be available for retrieval or review at any given time.
 
 Retention of Study Record s 
The site PIs are responsible for retaining study records for a period of [ADDRESS_992548] or, if no application is to be filed or, if a file application 
is not approved, until 2 years after the investigation is discontinued and the NRA is notified. PATH  will be 
responsible for providing the site with date of vaccine approval or IND/regulatory  withdrawal. No records 
will be destroyed without the written consent of PATH . PATH  will notify the investigator in writing when 
the trial related records are no lon ger needed.  
These records are also to be maintained in compliance with local IRB/ IEC and local authority medical 
records retention requirements, whichever is longest. Storage of all trial -related documents will be such 
that confidentiality will be strictly  maintained to the extent provided by [CONTACT_1769].   
CVIA 076 – Version 5.0 
17 February  2022 
 
 59  20 13.9  (0.0, 16.8)  (0.1, 24.9)  
25 11.3  (0.0, 13.7)  (0.1, 20.4)  
50 5.8 (0.0, 7.1)  (0.1, 10.6)  
70 4.2 (0.0, 5.1)  (0.04, 7.7)  
Minimum adverse event rates required to have ≥95% probability of detecting at least one such event with given sample sizes, 
along with two -sided 95% exact confidence intervals if 0 or 1 events are observed.  
Immunogenicity Evaluation 
Assessment of immunogenicity is a secondary objective in this study. Due to the prior vaccinations 
received by [CONTACT_726904], baseline immunity (titer of type -specific neutralizing 
antibody) to poliovirus  types [ADDRESS_992549] -vacci nation immunity is 
anticipated to exceed the assay upper limit of quanti fication (ULOQ) for some participant s, definitive 
comparisons of study vaccination groups to the relevant control (nOPV vs type -specific control, within 
cohort according to prior vacci nation [exclusively IPV vs OPV -containing]) will not be possible within this 
phase 1 study. Evaluation of immunogenicity, therefore, will be primarily descriptive in nature; 
comparisons to the relevant control will be made, but the sample size is not based on achieving a specific 
level of statistical power for these comparisons. Comparative evaluation for immunogenicity will focus on the cohorts previously receiving OPV vaccinations but will also be conducted among exclusively IPV -
vaccinated participant s. 
Prior studies of type 2 in OPV -vaccinated adult populations indicate baseline immunity within the 
quantifiable range, with mean  log
2 neutralizing antibody (NAb) titers ranging from 7.8 to 8.8 (unpublished 
data), and with the majority of participant s achievi ng NAb titer >ULOQ 28 days following a single dose of 
a Sabin -2 vaccine as well as investigational type 2 vaccines. Using a regression model permitting censoring 
at assay lower limit of quantification ( LLOQ ) and ULOQ, the standard deviation (SD) of post -vaccination 
NAb titers is estimated to be in the range of 3 – 3.5 on the log 2 scale, which is consistent with other 
published data for type 1 (prior to a boost vaccination in adulthood)  [11]. In the study involving type 2, 
the post- vaccination GMT ratio (candidate/control) and its corresponding CI were able to be estimated ; 
similar methods will be employed here (see below). With respect to binary immune response endpoints (seroconversion, oth er seroresponse rates), data from the type 2 study indicate seroconversion rates 
ranging from approximately 30% to 75%, depending on the vaccine and potency level administered. Rates of a minimum 2 -fold response ranged from approximately 50% to 75%, with r ates of any fold -rise ranging 
from approximately 60% to 85%. 
Using these values, simulation studies were conducted to evaluate the precision of estimates of the GMT, 
GMT rat i
o, response rates, and differences in response rates, assuming that 48 and 24 of the 50 and 25 
or 28 and 14 of the 30 and 15 prior OPV participant s randomized to receive nOPV or mOPV, respectively, 
provide samples for analysis. The figure below displays the average half -width of the two -sided 95% 
confidence intervals for the four evaluations across the range of relevant inputs (log 2 NAb SD for GMTs, 
true rate for  the various  response rates). The level of precision expected to be available, described within 
the figures, is considered adequate to determine if there is sufficient evidence of an immune response to warrant progressing into populations where the immune response may be more thoroughly described 
and compared.  
CVIA 076 – Version 5.[ADDRESS_992550], on average, that the CI for 
the difference in mean log 2 NAbs will be approximately ( -1.48, 1.48) with 48:24 or ( -1.92, 1.92) with 28:14 
when the estimated difference is 0 (ratio = 1), providing high confidence that the actual absolute log 2 
difference is <2 (ratio <4). If instead the SD is 2.0, the CI would be approximately ( -0.97, 0.97)  with 48:24, 
providing confidence that the actual absolute difference is <1 (rat io <2). For the lower sample size, with 
an SD of 2.0, the CI would be approximately ( -1.25, 1.25), providing high confidence that the actual 
absolute log 2 difference is <1.58 (ratio < 3). For the candidate vaccine group alone, assuming a SD just less 
than  3.5 and 48 evaluable subjects, the CI for the mean log 2 titer would be approximately ±1.0 log 2. That 
is, if the estimated GMT is 28 (256), the figure indicates the CI would be expected to be approximately (27, 
29), or equivalently (128, 512), on average. If instead the SD is 2.5 with 48 evaluable subjects, the CI would 
be expected to be approximately (27.3, 28.7), or equivalently (158, 416), on average.  
With respect to response rates, for which precision is naturally lower than the continuous measurement of serum NAbs: if a true response rate is 50% in each group (maximum variability), then the CI for the 
estimated candidate vaccine response rate would be expected to average ±15%  (± 20% for 28 evaluable 
subjects) from the point estimate, and the CI for the difference in response rates would be expected to 
average ±23%  (±30% for 28:14)   from the point estimate.  
 
 
Intestinal Immunity, Genetic Stability  
In recognition that previously OPV -vaccinated participant s are unlikely to shed vaccine virus in substantial 
quantities, the 30- 40 participant s for each type with exclusive prior IPV vaccination to be randomized 1:1 
to nOPV or mOPV are included primarily to provide a preliminary indication of intestinal take (shedding 
of virus, indicating replicating infecti on), as well as to provide samples for potential genetic stability 
analysis of shed virus, including NGS  and evaluation in a mouse neurovirulence assay. The relevant 

CVIA 076 – Version 5.0 
17 February  2022 
 
 61  neurovirulence assay for comparison to Sabin- strain vaccines is yet to be developed, but it is anticipated 
that a null hypothesis of no difference, vs. an alternative hypothesis of superiority of nOPV to mOPV will 
be evaluated from this model; a defined le vel of statistical power is not a requirement for this preliminary 
evaluation. It is currently unknown what levels of paralysis may be seen in transgenic mice in such an assay  as assay development is ongoing but based on preclinical data indicating no para lysis associated 
with passaged candidate vaccine virus, and the known reversion to neurovirulence resulting in frequent paralysis of mice inoculated with reverted Sabin- strain vaccines, sufficient discriminatory capability is 
expected to be provided by 15- 20 participant s per vaccine.  
 Definitions of Populations to be Analyzed  
11.4.1  Enrolled Population  
The Enrolled Population is defined as all participant s who provide informed consent, regardless of the 
participant ’s randomization and treatment status in the study. 
11.4.2  Safety Population  
The Safety Population is defined as all participant s in the Enrolled Population who received a study 
vaccine.  
11.4.3  Full Analysis Population  
The Full Analysis Population (FAP) is defined as all participant s in the Enrolled Population who were 
randomized, received a study vaccination, and provided a baseline and at least one post- study vaccination 
evaluable serum sample.  
11.4.4  Per-Protocol Population  
The Per-Protocol (PP) population is defined as all participant s in the FAP who correctly received all study 
vaccinations per randomization with no major protocol deviations that are determined to potentially interfere with the immunogenicity result of the participant . The PP population will be defined on the time -
point level; that is, a participant  may be evaluable in the PP population with their baseline and Day 29 
samples, but not for the Day 57 sample due to a major protocol deviation. For summaries of the PP population on the participant  level, the PP membership for the Day 29 visit will be used.  
Prior to database lock, the database will be searched for potentially disqualifying deviations. Additionally, 
protocol deviations will be collected from monitoring and medication listings will be reviewed; this 
information will be reviewed in a Data Review Meeting (DRM) attended by [CONTACT_726905] , 
Emmes , and the study sites to determine PP population eligibility. Efforts will be taken to blind particip ant 
group membership during this review to the extent possible in this o bserver -blind study. The following 
constitute potential criteria for elimination from the per -protocol population. The list is not exhaustive, 
as unexpected deviations may arise requiring unique consideration.  
• Missed vaccinations  
• Significant non- compliance with visit windows  
• Any eligibility  criteria not met  
• Receipt of a non -study vaccine  
• Receipt  of immunosuppressants or immune modulators  
• Receipt of study vaccine not stored as per manufacturers approved storage condition  
• Incomplete vaccine dose administration or vomiting within 5 minutes of vaccination 
CVIA 076 – Version 5.0 
17 February  2022 
 
 62  • Serological results unavailability  
• Wrong randomization 
• Dosed with wrong treatment arm  
 
A DRM report will provide the criteria used f or determination, as well as list the participant s excluded and 
accompanying rationale. 
11.4.5  Other  Population s 
The SAP will define additional subgroup participant  populations for specific analyses . 
 Analytical Methodology  
11.5.1  Descriptive Methodology  
All data  collected  will be summarized and/or listed. Analyses will be performed using SAS® software (SAS 
Institute Inc., Cary, NC, [LOCATION_003]) version 9.4 or higher. 
Unless otherwise specified, descriptive statistics include the mean, SD, median, minimum, maximum for 
continuous variables, and the number and proportion in each group for categorical variables. Unless 
otherwise specified here or in the SAP, statistical tests,  and confidence intervals (CIs) will be computed 
using a two -sided 5% significance level. Exact (Clopper -Pearson) CIs will be used for univariate summaries 
of dichotomous variables, and Miettinen- Nurminen score -based confidence intervals will be used for rate 
differences. All proportions will use as denominator the number of participant s contributing data  at the 
specified time point within the specified group and study population. 
Summaries will be presented by [CONTACT_65467], where relevant.  
For all summaries outlined below, the SAP will contain additional detailed description of the analyses to 
be conducted. 
11.5.2  Analysis Sequence  
Analysis of immunological endpoints will occur separately for each type, in advance of the completion of long- term safety follow -up of participant s. Following database lock for long -term safety follow -up and 
completion of stool viral shedding assays, a complete final analysis will be produced and incorporated into the clinical study report  (CSR) . 
11.5.3  Change s in Analysis Plan  
Any deviations or changes from the statistical analyses specified in the protocol will be described and 
justified in the SAP and the CSR. 
11.5.4  Baseline and Demographic Characteristics, and Participant  Disposition  
Descriptive statistics will be computed for demographic (e.g., height, weight, race, sex ) characteristics in 
both the safety and PP populations, and other initial participant  charac teristics (e.g. , medical and surgical 
history, concomitant diseases) in the safety population. 
Concomitant medications will be coded using the WHO Drug Dictionary. Medical history will be coded 
using the most recent version of the Medical Dictionary for Re gulatory Activities (MedDRA). 
CVIA 076 – Version 5.0 
17 February  2022 
 
 63  Participant  disposition including dropout and reasons for dropout, as well as study population 
membership will be summarized descriptively, and supported with a CONSORT (Consolidated Standards 
of Reporting Trials) diagram.  
Screening serology will be summarized descriptively, including HIV, HBV , and HCV, pregnancy testing, and 
type -specific anti-polio antibodies among all participant s, and in the enrolled population. 
11.5.5   Safety Analysis  
All safety analyses will be conducted in the safety population. Summaries will be computed separately by 
[CONTACT_19313], and within type across group (i.e., combined Groups 1 and 3 compared to combined Groups 2 and 
4, and combined Groups 5 and 7 compared to combined Groups 6 and 8).  
The exten t of exposure will be summarized by [CONTACT_726906] a given vaccine received 
for each participant , as well as descriptive summaries of the time (days) between vaccinations  
[IP_ADDRESS]  Solicited Adverse Events  
Solicited events will be summarized by [CONTACT_726907] s with observation of any 
event, and any event according to event type, over all vaccinations within groups, and for each vaccination individually within group. Additional analyses will summarize the frequency and durat ion of events 
ongoing at Day [ADDRESS_992551] 95% confidence intervals. Within cohorts  (separately for each type) , the 
rate of solicited adverse events will be compared using a two- sided Fisher’s exact test for pairwise 
comparisons, both overall and by [CONTACT_726908], and overall (across doses);  this will be 
repeated for severe and for moderate or greater events.  
[IP_ADDRESS]  Unsolicited Adverse Events  
All unsolicited adverse events will be listed and summarized in tables. Unless an AE is classified as an SAE, 
summaries of unsolicited AEs will be made using o nly those events recorded with onset within 28 days of 
the prior  vaccine dose. Unsolicited adverse events will primarily be summarized on the participant  level, 
where a participant  contributes once to a given event type under the maximum severity and/or causality, 
as appropriate. Tables will additionally display the number of events of a given type observed within a group, regardless of the number of participant s from which they ori ginate.  
Unsolicited adverse events will be summarized by [CONTACT_107239]; SAEs will be summarized overall, and by [CONTACT_726909]. In addition, all AEs, coded with MedDRA, will be 
summarized by [CONTACT_1196] (SOC) and P referred Term (PT), and separate tables by [CONTACT_726910] , severe AEs, related AEs, severe related AEs, and SAEs. A table will 
be prepared summarizing all preferred terms occurring in ≥ 2% of participant s. Additional summaries will 
include the rate of participant s experiencing an AE leading to withdrawal from vaccinations, or from the 
study. Additional listings will be prepared for severe AEs, related AEs, and SAEs. Within OPV type, the rates 
of participant s experiencing severe adverse events, related adverse events, and serious adverse events 
will be compared across groups using a two -sided Fisher’s exact test for pairwise comparisons.  
[IP_ADDRESS]  Safety Labs  
Each continuous hematology and chemistry laboratory test will be evaluat ed by [CONTACT_73967] (i.e., number of participant s, mean, SD, median, minimum, and maximum) on the actual values, 
CVIA 076 – Version 5.[ADDRESS_992552] values will be evaluated according to the t able for grading the s everity of 
adverse events  provided in this protocol or in accordance with the normal ranges of the clinical laboratory 
(below, within, or above normal range) for parameters for which no toxicity grades are defined. 
Clinical laboratory abnormalities will be summarized by [CONTACT_19313], parameter, time point, and grade, 
including the maximum grade post -baseline abnormality for each participant  for each parameter. 
Summaries will include any baseline abnormality across parameters within group, and any post -baseline 
abnormality across visits within parameters, as well as across parameters and visits. Abnormalities will also be summarized in a shift table, displaying the frequency of post -baseline abnormalities by [CONTACT_479] (with 
separate categories for high and for low values of a given lab, where relevant) cross -tabulated with the 
baseline classification for each time point for each lab. Boxplots will display the r aw value by [CONTACT_726911][INVESTIGATOR_726838], and those that are grade 2 or higher.  
[IP_ADDRESS]  Other Safety Measures  
Vital signs will be summarized descriptively, including change from baseline for  continuous measures. 
Vital sign abnormalities will be summarized descriptively.  
Abnormal findings in physical examination will be summarized descriptively.  
11.5.[ADDRESS_992553] analyses will be repeated in the FAP. All descriptive analyses will be conducted across all participant s within a group/time point 
combination, and these will be repeated for eac h site.  
[IP_ADDRESS]  Descriptive Analyses  
At each time point where NAb titers are obtained:  
- Median of log
2 antibody titers will be computed along with 95% CIs  
- GMT with accompanying 95% CIs will be computed. GMT s will be estimated with likelihood -based 
methods (SAS PROC LIFEREG) to accommodate censoring at assay ULOQ and LLOQ. 
- The geometric mean fold rise (GMFR) will be computed for each post -baseline time point as the 
reverse- transformed difference between the po st-baseline log 2 value and the baseline log 2 value  and 
accompanied by [CONTACT_1192] -sided paired- sample 95% CIs computed using asymptotic methods on the log 2 
scale, then reverse- transformed. A subgroup analysis of GMFR will consider only those participant s 
with valu es between the LLOQ and ULOQ (exclusive of the endpoints) for the numerator and 
denominator samples. For post -dose- 2 GMFR, this will be computed from baseline, and from the pre -
dose- 2 titer.  Among these participant s, a plot of the log 2 fold rise vs the baseline log 2 antibody titer 
will be generated.  
- Type -specific seroconversion rates with 95% exact CIs will be tabulated  for post -vaccination time 
points . Seroconversion rate will be computed among those participant s with seroconversion po ssible 
to observe (within 4- fold of the assay ULOQ). For post -dose- 2 seroconversion, seroconversion rates 
will be computed both from baseline and from the pre -dose- 2 titer  
CVIA 076 – Version 5.0 
17 February  2022 
 
 65  o In addition, the rate of any fold- rise (titer increased from baseline) and a minimum  2-fold 
rise in titer and accompanying CIs will be computed in the same manner  
- Type -specific seroprotection rate s with 95% exact CIs will be tabulated  
- Plots of the reverse cumulative distribution of antibody titers will be generated  
Additional figures will display immunity and changes in immunity over time, by [CONTACT_24975] . Additional subgroup 
computations will be specified and conducted, per the SAP.  
[IP_ADDRESS]  Comparative Analyses  
No specific immunogenicity hypothesis is to be tested. Descriptive comparative evaluation will be 
conducted with multiple endpoints; such evaluations will be conducted for the nOPV -vaccinated groups 
compared to the mOPV -vaccinated control groups within type, and within background vaccination cohort 
(within groups defined by [CONTACT_726912], and separately among those previously receiving OPV) . Separately for each pairwise comparison, the NAb GMT ratio (nOPV/mOPV) will be estimated via a 
linear model of the log
2 NAb  titer as a function of group with a fixed parameter for site and a covariate for 
the log 2 NAb titer level. This will be conducted using SAS PROC LIFEREG to account for censoring of the 
dependent variable assuming a Normal error distribution on the log 2 scale; baseline values achieving 
ULOQ or LLOQ will be replaced with ULOQ or LLOQ, as appropriate, for the covariate. The log- scale 
difference and its corresponding confidence interval, estimated with SAS LSMEANS, will be reverse -
transformed to obtain the estimated GMT ratio and corresponding 95% confidence interval. Among the subset of participant s where baseline and post -baseline NAb titers are below the assay ULOQ, the fold-
rise in titer will be computed, and these fold -rises will be compared between nOPV v s mOPV groups within 
background vaccination cohort and type using standard t-distribution methodology.  
Similar comparisons will be made for seroprotection rates, seroconversion rates, and other response rates (any fold- rise, 2 -fold rise). For these binary variables, two -sided 95% Miettinen and Nurminen confidence 
intervals for the rate difference (nOPV minus mOPV) will be computed, and these will be supplemented 
with a two -sided Fisher exact test p -value.  
Imbalance in baseline immunity between sites will be  evaluated via the Kruskal -Wallis test  for Nab titers . 
Wherever the global test is significant at two -sided level α = 0.10, pairwise comparisons will be drawn 
from the Wilcoxon test.  
11.5.[ADDRESS_992554] -dose 
period. The SAP will provide detail about participant s selected into each analysis.  
[IP_ADDRESS]  Descriptive Analyses  
For each group and time point, viral shedding positivity (PCR) a nd infectivity  (log
10 CCID 50 per gram) will 
be summarized. Additional summary of infectivity will be conducted only among those PCR- positive for 
(only) the vaccine virus. Positivity will be accompanied by [CONTACT_1192]- sided exact 95% confidence intervals for 
the pr oportion , and infectivity will be summarized with the median and bootstrap- based 95% CI. All 
samples will be evaluated for the appropriate virus type (1 or 3). Participant s PCR -positive for type- specific 
viral shedding of only the appropriate virus but wit h log 10 CCID 50 per gram equal to LLOQ will contribute a 
value equal to the LLOQ; participant s PCR -negative for viral shedding of the appropriate virus will 
contribute zero. A summary will also be produced for each post -dose period of the proportion of 
CVIA 076 – Version 5.0 
17 February  2022 
 
 66  participant s contributing any PCR- positive sample, any culture -positive sample ( ≥2.75 log 10 CCID 50 per 
gram), and those with log 10 CCID 50 per gram ≥4.0)  
The Shedding Index Endpoint (SIE) will be computed as the mean of the log [ADDRESS_992555] -dose (e.g., study days 8, 15, 22, and [ADDRESS_992556] 
dose). An additional summary table will describe the samples considered to be within- window for 
computation of the Shedding Index Endpoint.  Permissible stool sample windows will mirror the visit 
windows defined in this protocol . The SIE will be computed for each participant  contributing samples at 
each time point, and will be summarized by [CONTACT_19313], including the median and its bootstrap-b ased 95% 
confidence intervals. The SAP will define the AUC computations for each post -dose period, which will be 
summarized similarly.  
Time to cessation  of shedding is defined as the time (days) between vaccination and last PCR- positive 
stool prior to 2 consecutive PCR -negative stools  (with a minimum 24- hour interval between the 2 negative 
stools) . The time to cessation of shedding will be assessed with interval -censored methodology  to describe 
and compare the duration of shedding. Similarly, supplementary definitions of shedding negativity 
(culture -negative, defined as the last culture -positive value, and “transmission- negative”, defined as the 
last value with ≥4.0 log 10 CCID 50 per g ram) will be described in the SAP, and evaluated with methods 
accommodating censored data. The methods for considering participant s censored will be further defined 
in the SAP.  
Descriptive analysis and plots of the reverse cumulative distribution of the da ily infectivity assay results, 
the SIE, and the AUC  will be generated. Additional figures will display the shedding of virus over time.  
Additional subgroup analyses may be specified in the SAP.  
[IP_ADDRESS]  Comparative Analyses  
Comparisons of viral shedding data will be made within type and within background vaccination group 
(exclusively IPV and OPV -containing) . Rate of shedders (PCR, culture -positive, etc.) will be compared at 
each time point using summary statistics, as well as 95% score -based confidence intervals for the 
difference in proportions at each time point. The log [ADDRESS_992557] for the difference between groups, accompanied by [CONTACT_726913] -based 95% confidence interval, both overall and among only those PCR- positive 
for (only) the appropriate virus. The same methods will be used for the SIE and AUC. 
Tests between nOPV and mOPV for time- to-shedding cessation endpoints will be conducted with two -
sided l og-rank tests using a Type I error rate of 5%.  
11.5.[ADDRESS_992558] -vaccination stool samples. Briefly, 
transgenic mice susceptible to poliovirus will be inoculated with virus isolated and cell culture amplified 
from participant  stool samples, and the mice will be monitored and scored for presence/absence of 
paralysis. The proportion of mice paralyzed as a function of inoculum dose will be used to describe and 
compare the nOPVs to the corresponding mOPVs, according to OPV  type. The assay may include mice 
inoculated with relevant control material, and/or mice inoculated with the clinica l trial material, to 
compare to the resultant shed virus from participant s. 
CVIA 076 – Version 5.[ADDRESS_992559] access to all study related documents, source data/documents, 
and reports for the purpose of monitoring and auditing by [CONTACT_117850] , and inspection by [CONTACT_90471].  
 Study Monitoring  
PATH, the sponsor of this study is responsible for ensuring that the study is conducted in accordance with 
ICH GCP and regulatory requirements. For this purpose, monitors under contract from PATH  or its 
designees will provide external monitoring for this study. A site initiation visit will be conducted prior to 
beginning the study, and monitoring will be conducted during, and at closeout of the study.  During the 
study, the  monitors will visit the clinical site at intervals to verify compliance to the protocol, 
completeness, accuracy, and consistency of the data , study vaccine  accountability, and adherence to ICH 
GCP and applicable regulations. As needed and when appropriate, the monitors will also provide 
clarifications and additional training to help the site resolve issues identified during the monitoring visit. 
As appropriate and informed by [CONTACT_217149], remote centralized monitoring activities may be 
considered in place of or to supplement onsite monitoring. These may include analysis of data quality 
(e.g., missing or inconsistent data, outlier data ), and identifying data trends not easily detected by [CONTACT_726914] ( e.g.,  screening or withdrawal rates, eligibility violations , timeliness,  
and accuracy of data submission).  
The extent and frequenc y of the monitoring visit s will be described in a separate Study Monitoring Plan 
(SMP) developed prior to  study initiation. The investigator will be notified in advance of the scheduled 
monitoring visit. The monitor should have access to all trial related sites, participant  medical records, 
study vaccine  accountability and other study- related records needed to  conduct monitoring activities. 
CVIA 076 – Version 5.[ADDRESS_992560] and complete. The site PIs 
will permit auditors (employees of PATH  or employee of a company designated by [CONTACT_117850] ) to verify source 
data validation of the regularly monitored clinical study. The auditors will compare the entries in the eCRFs with the source data and evaluate the study site for its adherence to the clinical study protocol and GCP guidelines and applicable regulatory requirements. 
 Regulatory Agency Auditing  
The site PIs must be aware that  regulatory authorities, including IRB/IEC  may wish to inspect the site to 
verify the validity and integrity of the study data,  and protection of human research participants. The site 
PIs will notify PATH  within [ADDRESS_992561] the review of the current study or their  qualification as 
an investigator in clinical studies conducted by [CONTACT_117850] . PATH  will provide any needed assistance in 
responding to regulatory audits or correspondence.  
 ETHICAL CONSIDERATIO NS (AND INFORMED CONSENT ) 
 Ethical Standards  
This study will be  conducted in accordance with the ethical principles set forth in The Belmont Report: 
Ethical Principles and Guidelines for the Protection of Human Subjects of Research, as drafted by [CONTACT_726915]  E6 (R2) , 45 CFR Part 46 and 21 CFR 50.  
 Ethical Review  
Each participating institution will be responsible for assuring that this protocol and the associated ICFs 
and study- related documents are reviewed and approved by a n IRB/IEC  prior t o implementation of the 
protocol. Any amendments to the protocol, IC Fs, or other study- related documents must be approved by 
[CONTACT_1201]/IEC  and PATH  prior to implementation. A copy of the protocol, proposed IC F, other written 
participant  information, and any proposed advertising material will be submitted to each study site’s 
designated IRB/IEC  for written approval. The investigator must submit and obtain, as necessary, approval 
from the I RB/IEC  for all subsequent protocol amendments and changes to the IC F. The investigator will 
notify the I RB/IEC  of SAEs as noted in the protocol and of protocol deviations according to local regulatory 
authority and I RB/IEC  requirements. The study will be conducted in full compliance with the protocol. 
 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual agreeing to participate in the study and continues  throughout the individual’s study participation. Before any study -related activities and in 
agreement with applicable regulatory requirements, the site PI [INVESTIGATOR_726839] 076 – Version 5.0 
17 February  2022 
 
 69  informed about the aims, procedures, potential risks, and potential benefits of the study. The participant  
will be given the written, local IRB/ IEC approved IC F, allowed ample time to read the consent form, 
encouraged to ask questions about the study, have  the questions answered and then be given time to 
decide if they  would like to participate in the study. It will be emphasized that participation is voluntary, 
and that the participant  has the right to  decline to participate or subsequently w ithdraw from t he study 
at any time without prejudice.  
The site PIs or designees must obtain the participant ’s voluntary, signed,  and dated IC F before any study-
related procedures are performed. Study staff must document the informed consent process. The original, 
signed ICF must be kept in the site study file.  A copy of the informed consent document will be given to 
the participant s for their records.  
For each participant, following ICF signature, as further evidence that the comprehension requirement of informed consent  is fulfilled, an informed consent comprehension assessment will be used in the form of 
an open -ended questionnaire  to assess the participant’s recall of information related to study 
investigational procedures  and expectations regarding hygiene. 
The informed consent process and the informed consent comprehension assessment  may be undertaken 
using electronic systems and processes, provided designated IRB/IEC approval , and provided that there is 
adherence to the guidance provided in the FDA document “Use of Electronic Informed Consent. Questions and Answers. Guidance for Institutional  Review Boards, Investigators,  and Sponsors . December 2016.”  
 Participant  Confidentiality   
The investigator s, PATH  and all staff from organizations involved with the implementation of the trial  must 
ensure that the participant ’s confidentiality is maintained. Personal identifiers will not be included in any 
study report.  All study records will be kept confidential to the extent provided by [CONTACT_228927].  
Medical records containing identifying information may be made available for review when the study is monitored by [CONTACT_726916]. Direct access may include examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the study.  
When appropriate and to the extent possible, study procedures will be conducted to protect participant  
privacy and confidentiality.  
All study- related infor mation will be stored securely at the study site. All participant  information will be 
stored in locked file cabinets in areas with access limited to study staff.  Data collection, process, and 
administrative forms, laboratory specimens, and other reports will be identified by a coded number only to maintain participant  confidentiality. All records that contain names or other personal identifiers, such 
as locator for ms and ICFs, will be stored separately from study records identified by [CONTACT_105751]. All local 
databases will be secured with password -protected access systems. Forms, lists, logbooks, appointment 
books, and any other listings that link Participant  ID numbers to other identifying information will be 
stored in a separate, locked file in an area with limited access. Participant s’ study information will not be 
released without their written permission, except as necessary for monitoring.  
 Reimbursement  
Pending local EC approval, participant s will be compensated for their time and effort in this study and be 
reimbursed for travel to study visits. The study IC F will state the plan for reimbursement. Participant s will 
not be charged for study vaccinations , research  clinic visits, research -related examinations, or research -
related laboratory tests.  
CVIA 076 – Version 5.[ADDRESS_992562] benefits from  their participation in this research study. Participant s 
may indirectly benefit from the clinical assessments (medical history, physical examination,  and routine 
clinical safety laboratory tests) conducted at screening and during the study. If the participant  is found to 
have any newly diagnosed medical condition or infection,  the investigator will ensure that the participant  
is provided with appropriate and adequate referrals within the health care system.  Participation in this 
study will hopefully contribute to development and eventual deployment of a vaccine to address a glo bal 
public health concern. 
Preclinical testing of the two nOPVs  (nOPV1 and nOPV3) to be assessed in this study have not identified 
specific, inherent risks of these products. There are currently no clinical safety data  for nOPV1 or nOPV3  
as they have  not yet been tested in humans ; however,  a similar nOPV, against type 2 poliovirus  (nOPV2) , 
has been assessed in p hase [ADDRESS_992563] also been observed following immunization with Sabin OPV; therefore, in this 
study, the AEs that will be actively solicited in the one week  following administration of the study vacci nes 
include such events, specifically, fever,  chills, fatigue, headache, myalgia s (muscle aches) , arthralgias (joint 
aches), nausea, vomiting, abdominal pain, and diarrhea . 
The most concerning risks for the Sabin OPVs  are VAPP and the introduction of VDPV into vulnerable 
populations. VAPP, in which vaccine administered to an individual reverts to virulence (a risk the nOPVs are designed to avoid) and results in paralytic polio in that individual, occurs in approximately [ADDRESS_992564] provocation poliomyelitis, 
participant s will be prohibited from the receipt of any intramuscular injection for 30 days , prior to or 
following each study vaccination (except seasonal inactivated influenza and COVID -19 vaccines, which are 
prohibited for 14 days) . 
Risks associated  with contamination with shed vaccine virus, and potential transmission to others, is to 
be mitigated by [CONTACT_726917][INVESTIGATOR_841] , at least until cessation of 
shedding of vaccine virus by [CONTACT_726918] . As component s of such strict hygienic practices, 
study participants will be counseled to : 
• flush toilet with toilet lid closed, and then sanitiz e the toilet surfaces  
• use hygienic techniques to  obtain and handl e stool specimens  
• wash hands after toilet use  
• wash hands before handling food 
• shower prior to entering public swimming pools and avoi d spas and hot tubs  
CVIA 076 – Version 5.[ADDRESS_992565] precautions [ 12]. The site laboratory 
processing the stool specimens must meet BSL -[ADDRESS_992566] 
study staff as soon as possible. Participant s will be encouraged to be evaluated at the study clinic, if 
CVIA 076 – Version 5.0 
17 February  2022 
 
 72  possible. If participant s seek medical care outside the study clinic, they should inform the health care 
provider(s) of their participation in this study, provide the health care provider(s) with contact [CONTACT_726919], and separately contact [CONTACT_726920]. There are limited funds available to the study for care of study- related injury, in addition 
to modest no- fault insurance for study- related injury. In addition, both PATH, the Sponsor, and Bio Farma, 
the vaccine manufacturer, will have liability insurance coverage for the trial. Although the investigators 
and PATH  will make every effort to cover the costs of any stu dy-related injury, full coverage cannot be 
guaranteed, and uncovered costs may fall on participant s and/or their insurers. Participant s will be 
reimbursed to the extent possible for costs of medical care necessary for any study -related injury. 
Participant s will be informed of the limitations for coverage of study- related care costs and that there is 
the possibility that they may ultimately be responsible for at least some of the cost of care.  
 FINANCING AND INSURANCE  
The trial is supported by a grant from the Bill and Melinda Gates Foundation to PATH. Funding of the sites and Emmes ’ activities will also be covered by [CONTACT_726921]. Bio Farma will be providing 
pharmaceutical support through the provision of the clinical study vaccines .  
PATH will secure insurance that complies with the applicable regulatory and legal requirements.  
 PUBLICATION POLICY  
According to the policy of the International Committee of Medical Journal Editors (ICMJE) member journals, this clinical trial will be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_726922].  
The information generated in this study will be used by [CONTACT_726923] , as well 
as global public health organizations, such as the World Health Organization. PATH (or designee)  will 
prepare a CSR according to ICH -E3 guidelines. PATH  and Bio Farma recognize the importance of 
communicating study findings and will therefore encourage their publication in reputable scientific journals and presentation at seminars or conferences, while protecting the integrity of the ongoing trial. Study results will be made publicly available in compliance with the WHO mandated timeframe for public 
disclosure of results from clinical trials. Any publication, lecture, manuscripts of the findings of this study 
by [CONTACT_726924]. The ICMJE authorship criteria will be strictly followed for publication of any manuscripts 
arising from this trial . Within any presentation or publication, confidentiality of individual participant s will 
be maintained, with identification by [CONTACT_726925], if applicable . 
 
  
CVIA 076 – Version 5.0 
17 February  2022 
 
 73  
 REFERENCES 
 
[1] GPEI -cVDPV -factsheet:  http://polioeradication.org/wp- content/ upl oads/2018/07/GPEI -cVDPV -Fact-
Sheet -20191115.pdf  
[2] WHO. Wkly Epi[INVESTIGATOR_75313]. No 46, 2019, 94, 525– 540 
[3] Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, et al. Engineering the Live -Attenuated Polio 
Vaccine to Prevent Reversion to Virulence [published online ahead of print, 2020 Apr 10]. Cell Host 
Microbe. 2020; S1931- 3128(20)[ZIP_CODE]-4 
[4] Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV Jr. Quantitation of poliovirus 
antigens in inactivated viral vaccines by [CONTACT_28745] -linked immunosorbent assay using animal sera and 
monoclonal antibodies. J Biol Stand. 1989; 17:137– 50 
[5] Minor P.D., Ferguson M., Katrak K., Wood D., John A., Howlett J., et al . Antigenic structure of 
chimeras of type [ADDRESS_992567]; 
72:2475- 81 
[6] Minor P.D., Macadam, A.J. Personal communication on m onoclonal antibodies  for type 3 available at 
NIBSC  
[7] Ohka S, Igarashi H, Nagata N, Sakai M, Koike S, Nochi T, et al .  Establishment of a poliovirus oral 
infection system in human poliovirus receptor -expressing transgenic mice that are deficient in 
alpha/b eta interferon receptor.  J Virol. 2007 Aug;  81(15):7902- 12 
[8] Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S,  et al . Evaluation of 
immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method 
for predicting vaccine efficacy. J Infect Dis. [ADDRESS_992568] 15;  190(8):1404- 12 
[9] Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P , et al. The safety 
and immunogenicity of t wo novel live attenuated monovalent ( serotype 2) oral poliovirus vaccines in 
healthy adults: a double -blind, single -centre p hase 1 s tudy. Lancet. 2019;  394([ZIP_CODE]):148- 158 
[10] Caceres  VM, Sutter  RW.  Sabin monovalent oral polio v accines:  review of p ast experiences and t heir 
potential use after polio e radication . Clin Inf ect Dis. 2001 Aug 15;  33(4):531 -41 
[11] Eggers  M, Terletskaia- Ladwig E, Rabenau HF, Doerr HW, Diedrich S, Enders G,  et al . Immunity status 
of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc- 2ab) in Ger many. 
BMC Infectious Diseases . 2010 Dec 9 ; 10:347 
[12] Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices 
Advisory Committee . 2007 Guideline for Isolation Precautions: Preventing Transmission of I nfectious 
Agents in Healthcare Settings  https://www.cdc.gov/infectioncontrol/guidelines/isolation/in dex.html   
  
CVIA 076 – Version 5.0 
17 February  2022 
 
 74  APPENDI CES 
APPENDI X 1:  SCHEDULE OF STUDY VISITS AND EVALUATIONS   
Participant s with an Exclusive IPV Vaccination History (Cohorts 1 and 3: Single -dose groups ) 
Procedure  Screen  Visits  
   
Visit Name  00 01 01A 01B 02 02A 02B 02C 03 03A 03B 03C 03D 04 
Study Day  (allowed window days)  -90 to 1 1 3 5 8 (+1) 10  15 22 29 (+2) 36 43 50 57 169 
(+14)  
Clinic visits  X X   X    X      
Stool collection    X X X# X# X# X# X# X X X X1  
Allowed stool collection window 
(days)    ±1 ±1 D8±1  ±1 ±2 ±2 D29±3 ±1 ±2 ±2 ±3  
Informed consent  X              
Eligibility criteria  X X                 
Demographic data  X                  
Medical history  X                
Concomitant medication  X X2 
Full physical exam  (PE) with VS X              
Vital signs (VS)   X             
Targeted PE with VS, if indicated   X   X    X     X4 
Blood for HIV1/2, HBsAg, HCV Ab, 
total IgG & IgA, pregnancy in FOCP  X     
          
Blood for CBC  & chemistry  X X3   X          
Blood for type-specific poliovirus  
neutralizing Ab  X        X      
Urine pregnancy in FOCP   X             
Randomization    X5             
Study vaccine    X             
Collect solicited AEs   X  
Collect unsolicited AEs   X  
Collect SAEs   X 
 
CVIA 076 – Version 5.0 
17 February  2022 
 
 75  #  – Participants may contribute additional stool samples between study Days 8 and 28, in addition to the nominal study stool sampling days, if 
available.  
X1 – If cessation of vaccine virus shedding not confirmed, collections will continue until cessation confirmed  
X2 – Only those associated with SAE s or COVID -19 vaccinations  
X3 – The results of these laboratory tests are not required for eligibility, but will be used as baseline for analyses  
X4 – Day 169 assessments will be performed via telephon e. The participants will only come to the clinical if a physical exam is indicated.  
X5– Randomization can be done prior to Day 1 after confirmation of eligibility .  
  
CVIA 076 – Version 5.0 
17 February  2022 
 
 76   
Participant s with an OPV-Containing  Vaccination History ( Cohorts 2 and 4: Two -dose groups)  
Procedure  Screen  Visits  
Visit Name  00 01 02 02A 02B 03 04 04A 04B 05 06 
Study Day  (allowed window days)  -90 to 1 1 8 (+1) 15 22 29 (+2) 36 (+1) 43 50 57 (+2) 169 (+14)  
Clinic visits  X X X   X X   X  
Stool collection    X X X X X X X X1  
Allowed stool collection window 
(days)    D8±1  ±2 ±2 D29±3 D36±1 ±2 ±2 D57±3  
Informed consent  X           
Eligibility criteria  X X    X      
Demographic data  X           
Medical history  X           
Concomitant medication  X X2 
Full physical exam (PE) with  VS X           
Vital Signs (VS)   X    X      
Targeted PE with VS, if indicated   X X   X X   X X4 
Blood for HIV1/2, HBsAg, HCV Ab, 
total IgG & IgA, pregnancy in FOCP  X           
Blood for CBC  & chemistry  X X3 X         
Blood for type-specific poliovirus  
neutralizing Ab  X     X    X  
Urine pregnancy in FOCP   X    X      
Randomization   X5          
Study vaccine   X    X      
Collect solicited AEs   X  X  
Collect unsolicited AEs   X  
Collect SAEs   X 
 
X1 – If cessation of vaccine virus shedding not confirmed, collections will continue until cessation confirmed  
X2 – Only those associated with SAE s or COVID -19 vaccinations  
X3 – The results of these laboratory tests are not required for eligibility, but will be used as baseline for analyses  
X4 – Day 169 assessments will be performed via telephone.  The participants will only come to the clinical if a physical exam is indicated.  
X5 – Randomization can be done prior to Day 1 after confirmation of eligibility.  